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Herpes simplex virus type 1 (HSV-1) infected cell polypeptide 4 (ICP4) is a critical regulator of 
viral gene expression that is required for productive infection. ICP4 has been shown to act, 
depending on the promoter structure, as both an activator or repressor of viral genes.  ICP4 has 
two broad transcriptional regulatory domains, the N-terminal domain, which exhibits both 
repression and transactivation, and the C-terminal domain, which is involved exclusively in 
transactivation.  ICP4 regulates transcription through interactions between ICP4’s transcriptional 
regulatory domains and cellular general transcription factors including components of TFIID.  
Although it has been shown that a region in the amino-terminus of ICP4 corresponding to aa 30-
210 is necessary for appropriate transactivation and repression of viral genes, specific domains 
responsible for these activities remain uncharacterized.  Using deletion mutants spanning this 
region, we show that the entire region is necessary for ICP4 function, but that loss of aa 30-142 
has a greater detrimental impact on the ability of ICP4 to transactivate E and L genes.  Neither 
deletion had a significant impact on ICP4 repression, however.   
The protein interactions made by ICP4 in vivo during infection were also studied.  We 
show ICP4 forms complexes with TFIID, thus verifying previous in vitro data.  Novel 
interactions between TFII-I and components of the Mediator complex were also identified.  In 
addition, Mediator was found to colocalize with ICP4 starting at early and continuing into late 
times of infection.  Mediator was also recruited to viral promoters in an ICP4-dependent manner, 
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showing a direct role for Mediator in ICP4-mediated transcription.  Together, the data show that 
ICP4 regulates transcription through interactions between its complex regulatory domains and a 
diverse set of cellular protein complexes, including components of the basal transcription 
machinery and coactivator complexes. 
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1.0  INTRODUCTION 
1.1 HERPESVIRIDAE 
The order Herpesvirales comprises a diverse group of DNA viruses that are highly disseminated 
throughout our environment with hosts in nearly all vertebrate species.  Traditionally, these 
viruses have been identified based on morphology.   A herpesvirion consists of a core with a 
linear, double-stranded genome ranging from 124-230 kilobases. Surrounding the core is an 
icosahedral capsid that is approximately 125 nm in width and comprised of 162 capsomeres. 
Surrounding the capsid is an amorphous, proteinacious tegument layer. Finally, surrounding the 
tegument is a lipid bilayer envelope with glycoprotein spikes (210).  Further subdivision of the 
order defines three families: Alloherpesvirdae which infect fish and amphibians, 
Malacoherpesvirdae which infect bivalves, and Herpesviridae which infect mammals, birds, and 
reptiles (175).  Over 200 members of Herpesviridae have been identified with most animal 
species susceptible to infection by one or more members.  In humans, there are currently eight 
known herpesviruses: herpes simplex virus 1 and 2 (HSV-1, -2) also known as human 
herpesvirus 1 and 2 (HHV-1 and HHV-1), Varicella zoster virus (VZV, HHV-3), Epstein-Barr 
virus (EBV, HHV-4), cytomegalovirus (CMV, HHV-5), HHV-6, HHV-7, and Kaposi’s sarcoma-
associated herpesvirus (KSHV or HHV-8) (210).  
 2 
Herpesviridae contains three sub-families (alpha, beta and gamma).  These were 
historically based on the host-range and tissue specificity, the duration of the replicative cycle, 
and the cell-type that harbors latent infection (235) but are now based on genomic organization 
and gene sequence.  Hallmarks of the Alpha-herpesviruses are a relatively broad host-range, 
short replicative cycle, and latency in sensory neurons.  Members that infect humans consist of 
HSV-1 and -2 as well as VZV.  The Beta-herpesviruses have a longer replication cycle and a 
restricted host-range compared to the alpha-herpesviruses. This sub-family establishes latency in 
secretory glands, lymphoreticular cells, and the kidneys.  Members of the Beta-herpesviruses that 
infect humans include CMV, HHV-6, and HHV-7.  The third sub-amily are the Gamma-
herpesviruses.  Members have a host-range restricted to the family or order to which the natural 
host belongs, have a variable replication rate, and are also lymphotrophic. Gamma-herpesviruses 
include EBV and HHV-8 (210).  
The human herpesviruses are significant pathogens with many members being endemic 
to the human population. The clinical manifestations of infection are diverse. HSV-1 and -2 
primarily cause orolabial and genital epithelial lesions and can rarely lead to encephalitis.   VZV 
is the causative agent of chickenpox and zoster, which can lead to a painful and potentially 
debilitating neuralgia.  Recurrent reactivations from latency of HSV leading to infections of the 
eye can also cause herpes keratitis, the leading cause of infectious blindness in the developed 
world.   CMV causes a wide-range of diseases predominately in immunocompromised 
individuals.  Manifestations are most severe in congenital infections potentially leading to mental 
retardation or vision and hearing loss. Pathology of CMV infection also includes CMV 
mononucleosis, CMV retinitis, and GI disease.  HHV-6 and -7 cause roseola infantumin in 
infants and can lead to more significant complications in immunosuppressed individuals.  EBV is 
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the causative agent of mononucleosis and B cell lymphomas while KSHV is associated with 
Kaposi’s sarcoma (236). 
1.2 HSV PATHOGENESIS 
HSV enters the host via infection of skin and mucosa epithelial cells primarily in the orolabial or 
genital region and is spread by close person-person contact.  The virus replicates its DNA in the 
nucleus of infected cells, producing progeny virions that spread to neighboring cells. Egress 
results in the death of the infected cell.  This presents as lesions or blisters at the site of infection 
(236).  During the course of infection, the virus enters the sensory neurons that inervate the site 
of infection. The virus infects the neurons and the capsid travels via retrograde transport to the 
cell bodies of the sensory ganglia. Given the areas typically involved with infection, the 
corresponding sensory ganglia include the trigeminal or sacral ganglia.  In these ganglia, the 
genome establishes an asymptomatic latent infection in the nuclei (40, 274).   
 During latency, the viral genome persists in a quiescent state with little gene expression 
other than the abundant expression of the latency-associated transcripts (LATs) (218, 244, 288).  
The genome associates with histones in a repressive nucleosomal structure and endures in an 
episomal, circular configuration (53, 181).  Dynamic interactions between HSV, the neuron, and 
the host immune system contribute to the maintenance of latency (44).  CD8+ T-cells associate 
with latently infected neurons and may inhibit viral reactivation through the release of IFN-? and 
lytic granules that cleave viral proteins important in viral lytic replication (137, 141).  
Environmental and physiological stresses, including UV-light, fever, malnutrition, fatigue, or 
anxiety lead to a de-repression of the viral genome, and also immunosuppression and loss of the 
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CD8+ T-cell functions involved in surveillance of the infected neuron, which results in 
reactivation (79, 288).  Once reactivated, the virus enters the lytic replication cycle, producing 
progeny virions that travel down the axon via anterograde transport. This reactivation is often 
asymptomatic but can lead to recurrence of clinical manifestations at the site of the primary 
infection and allows for the dissemination of the virus to new hosts (40). 
1.3 HSV GENOME CONFIGURATION 
The HSV genome consists of a large (~152 kb), linear double-stranded DNA molecule with a G 
+ C content of approximately 68% (138).  Within the virion, the DNA molecule contains nicks 
and gaps, which may serve to activate host DNA repair processes upon entering the nucleus (80, 
234).   The genome is divided into two covalently linked subunits, the L and S regions (figure 1) 
that contain unique sequences (UL and US) of about 108 and 13 kb, respectively. These regions 
are flanked by inverted repeats (RL and RS) (reviewed in (173)).  The terminal repeats are in a 
direct orientation with the internal repeats inverted; thus, RL is described by ab and b’a’ while the 
RS is a’c’ and ca (162).  The structure of the a sequence is highly conserved. However, it 
contains a variable number of repeats depending on the HSV strain, and so it ranges in length 
between 250-500 bp (234).  There is a constant single copy of the a sequence at the S terminus 
but variation in the number of repeats abounds at the L-S junction and the L terminus (162).   
Different isolates of HSV can therefore have genomes that range in size up to 10 kb (287). 
The presence of the repeat elements allows for recombination between the terminal direct 
repeats and the internal inverted repeats.  This causes the inversion of the unique and repeat 
sequences relative to one another and leads to four distinct isomers of the genome in equimolar 
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proportions: no inversion, UL inversion, US inversion, and both UL -US inversion (45, 111).  All 
four isomers can arise from infection with a single isomer.  Deletion of the internal repeat 
sequences, which prevents production of the various isomers, has no discernable effect on viral 
replication in tissue culture but is important for viral pathogenesis (234).  As opposed to the 
expendable internal a sequences, the terminal a sequences are important for both 
concatemerization and packaging of the genome, and thus are required for replication (3, 117).  
The genome also includes three origins of replication with one in the UL region (oriL) and one 
repeated copy in the RS (oriS) (236). 
 
Figure 1:  Schematic representation of the structure of the HSV genome. 
The HSV genome is divided into two unique regions, Unique long (UL) and Unique short (US).  These regions are 
bracketed by repeats RL and RS indicated by arrows.  The RL repeat is composed of elements: the a (red) and b (blue) 
sequences while the RS is composed of a and c (green) sequences.  The terminal direct repeats (ab and ca) are 
inverted in the junction (b’a’ and a’c’).  A single copy of the a sequence is found at the US terminus, while varying 
copy numbers are found at the the UL terminus and junction region. 
 
The HSV genome encodes approximately 80 open reading frames utilizing both DNA 
strands (173).  The UL region contains at least 56 genes associated with viral DNA replication, 
virion structure, and ICP27. The US region encodes 12 glycoproteins, ICP22, and ICP47 among 
others.  The RS contains the ORF for ICP4 while RL contains the ICP0 ORF. Thus there are two 
copies of both the ICP4 and ICP0 genes per genome (236).   HSV genes are similar in structure 
to cellular genes with a promoter, an ORF, 3’ UTR and a polyadenlyation signal (10).  However, 
only 5 viral genes contain introns which are abundant in cellular genes (213, 236).  Exploiting 
this difference is one way the virus promotes viral over cellular gene expression.   
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1.4 HSV PRODUCTIVE LIFE CYCLE 
The HSV productive cycle begins with entry of the virus into the cell via binding of the virion to 
the cell surface through specific receptor interactions. This binding leads to fusion of the 
envelope with the cell membrane (reviewed in (270)).  The de-enveloped virion is then 
transported to the nuclear pore complex (NPC) where the viral DNA is injected into the nucleus 
(267).  The viral gene expression program then begins in the nucleus and proceeds in a tightly 
regulated cascade consisting of three broad stages, the Immediate Early (IE, or ?), Early (E or ?), 
and Late (L or ?) (120, 121).  The IE genes primarily coordinate the viral gene expression 
program; E genes are involved in DNA replication; and L genes encode mostly structural 
proteins.  Once sufficient E proteins are present, viral DNA replication commences.  Following 
DNA replication, L genes are expressed, allowing for capsid assembly, encapsidation, and 
egress. 
1.4.1 Viral entry 
Viral entry proceeds through two distinct pathways.  The first pathway involves fusion of the 
viral envelope with the plasma membrane whereas the second involves endocytosis of the 
enveloped virion and subsequent fusion of the envelope in endocytic vesicles (reviewed in 
(236)).  Although the second pathway is well characterized in certain tissue culture models, its 
importance during clinical infection is unclear.  The first step of entry is the attachment of the 
virion to the cell surface through interactions between gC and gB in the viral envelope and cell 
surface glycosoaminoglycans (GAGs) (113, 259, 272, 301).  gB is essential for viral replication 
whereas gC is nonessential in tissue culture although the deletion of gC results in reduced viral 
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entry (113).  Attachment of the virus to the cell surface triggers the interaction of gD with one of 
its receptors and, in conjunction with gB, gH, and gL, fusion of the envelope with the cellular 
membrane (reviewed in (271)).  Receptors for gD include intercellular adhesion molecules called 
nectins, herpes virus entry mediator (HVEM) -a member of the tumor necrosis factor receptor 
family- and 3-O-sulfated heparan sulfate (34, 85, 187, 260).  Once the capsid is released into the 
cytoplasm, it is transported via the microtuble network to the NPC through interactions with the 
cellular motor protein dynein (57, 267).  Once at the NPC, the capsid binds to the pore and 
injects the viral DNA into the nucleus in a poorly understood mechanism that is dependent on 
both energy and importin ? (56).  Viral gene expression commences shortly after the genome 
gains access to the nucleoplasm. 
1.4.2 Viral DNA replication 
There are seven HSV genes required for viral DNA replication (19).  These include the DNA 
polymerase holoenzyme heterodimer comprised of UL30 and UL42, the origin-binding protein 
UL9, single-stranded DNA binding protein ICP8, and the DNA helicase-primase complex 
comprised of UL5, UL8, and UL52 (reviewed in (236)).  DNA replication can begin from any of 
the three origins of replication while none of them are specifically required (125, 215).  Once the 
viral gene expression program proceeds adequately to accumulate sufficient levels of E proteins, 
viral DNA replication commences.   
Traditionally, the viral genome was thought to circularize shortly after entering the 
nucleus and serve as the template for DNA replication while in the circular form (214).  Based 
on this circular model, viral replication was thought to proceed first through theta replication 
followed by a switch to rolling circle replication resulting in long end-to-end concatemers (19).  
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More recently, it has been shown that ICP0 expression inhibits the circularization and so the 
linear molecule persists to serve as the DNA replication template (130).  Recombination-
dependent replication has been suggested as a possible alternative mechanism for viral DNA 
replication that would proceed from a linear template (196, 297).  The structure of the replication 
template and the mode of replication, however, remain controversial. 
1.4.3 Viral encapsidation and egress 
Late genes are expressed to maximal levels after the onset of DNA replication.  These genes 
encode the structural proteins required for the encapsidation, envelopment, and ultimate egress of 
the mature virion.  The viral capsid is composed of four proteins, the major capsid protein VP5, 
VP23, VP19C, and VP26 (reviewed in(117)).  Capsids are assembled around a scaffold. A viral 
protease removes the scaffold and concurrently the viral DNA enters the capsid.  DNA is added 
in unit length genomes through cleavage of concatemers by the terminase complex made up of 
UL15, UL28, and UL33 (3, 14).  Cleavage and removal of the scaffold and addition of the DNA 
triggers maturation into C-capsids, which are then tegumented, enveloped, and released from the 
cell. 
Viral egress from the cell is a complicated, multi-step process that is not fully understood.  
First, mature C-capsids exit the nucleus through an envelopment-deenvelopment process at the 
nuclear membrane (261).  The capsid is enveloped at the inner nuclear membrane, passes 
through the perinuclear space and subsequently fuses with the outer nuclear membrane (183).  
The deenveloped capsid is released and transported to the golgi where it is reenveloped.  The 
golgi vesicle containing the enveloped capsid then fuses with the outer membrane, releasing the 
mature virion from the cell.  How and when the capsid acquires the tegument is not well 
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understood but appears to be a dynamic process during egress and may play a role in 
coordinating the egress of the mature virion (51, 52, 182, 183). 
1.5 GENERAL OVERVIEW OF CELLULAR TRANSCRIPTION 
Understanding cellular transcription is essential for determining how HSV utilizes the machinery 
for its own transcription.  The successful regulation of gene expression is necessary for all forms 
of life.  The human genome is estimated to have between 20,000 - 25,000 protein-encoding 
genes, making the regulatory system overseeing their proper expression necessarily very 
complex (1).  There are several regulatory stages, including but certainly not limited to 
controlling access to the DNA template itself, recruitment of RNA polymerase to the gene of 
interest, initiation of transcription, the elongation of the transcript, splicing, polyadenylation, 
export of the mRNA from the nucleus, mRNA stability, and translation.  HSV encodes proteins 
that target each stage to enhance its own gene expression at the expense of the host cell.  A major 
site of regulation both for the cell and HSV is the recruitment and stabilization of RNA pol II to 
promoters. This proceeds through the formation of a preinitation complex (PIC) on the core 
promoter.   
The PIC consists of the cellular general transcription factors (GTFs) TFIID, TFIIA, 
TFIIB, TFIIF, TFIIE, and TFIIH and RNA polymerase II (pol II) (18, 134, 139).   TFIID, a large 
complex consisting of TBP and its associated factors (TAFs), is the first GTF to bind to the 
promoter through interactions with the TATA box and other core promoter elements.  Following 
TFIID binding, the remaining GTFs and pol II are recruited (21, 193).  Upstream activators act 
through general cofactors to both recruit and stabilize TFIID binding to the promoter as well as 
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recruit and stabilize the other GTFs and pol II to TFIID to form the final PIC (278).  General 
cofactors, such as TAFs and the Mediator complex, act as intermediaries bridging the upstream 
activators with the GTFs to stabilize PIC formation (reviewed in (278)).  Thus, activated 
transcription is a result of complex interactions between upstream activators, general cofactors, 
and GTFs to form stable PICs at promoters. 
1.5.1 Core promoter elements 
The promoter can be divided into two different regions, the core promoter region and the 
regulatory elements (reviewed in (278)).  The core promoter generally consists of those 
regulatory elements that influence transcription within 40 or 50 base-pairs (bp) both up- and 
downstream of the transcription start site.  Regulatory elements are those cis-acting elements that 
bind repressors and enhancers of transcription and fall outside of the core promoter region. The 
core promoter functions primarily to interpret the regulatory input from distal enhancers and 
repressors as well as orient the transcription machinery for proper transcription initiation through 
binding of the general transcription machinery.  Viral IE and E promoters include both core 
promoter regions and regulatory elements whereas L promoters consist of just a core promoter.  
Several elements and the proteins that recognize them have been defined, however only those 
elements relevant to HSV infection will be discussed further.   
The first core promoter element characterized, and one shared by all HSV promoters, is 
the TATA box.  The TATA box has a consensus sequence of TATA(A/T)A(A/T)(A/G) and is 
localized -31 to -24 bp relative to the start site.  The TATA box binding protein (TBP) binds to 
the TATA box and is one of the first proteins recruited to the promoter (reviewed in (264)).  
Although the TATA box was initially thought to be a feature of all promoters and the key way 
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they were recognized by the general transcription machinery, recent genome-wide analyses show 
that as little as 10% of human promoters include this element (10, 54).  Interestingly, promoters 
that contain the TATA box element tend to have a strictly defined transcription start site within a 
few base-pairs and are tightly regulated (21, 173). 
The other major promoter element found on HSV promoters is the Inr element.  It has a 
consensus sequence of YYA+1N(T/A) YY (where Y is pyrimidine and N is any nucleotide) and 
also serves as a binding site for TAF1/TAF2 components of TFIID (23, 181).  It can direct 
transcription either alone or in conjunction with other core elements such as the TATA box (63, 
161, 262).  In addition to components of TFIID, the cellular factor, TFII-I, has also been shown 
to recognize and bind the Inr element and play a role in Inr-driven transcription (168, 238).  
While not found on all HSV promoters, the Inr sequence is a common element of L promoters 
and is required for their proper expression (93, 140). 
1.5.2 General transcription factors 
Transcription initiation proceeds through an ordered recruitment of several different protein 
factors, termed the general transcription factors (GTFs) (21, 190, 202).  Initially defined as those 
crude fractions separated by column chromatography that are required to reconstitute site-
specific transcription in vitro using purified RNA pol II, these six factors were termed TFIIA, 
TFIIB, TFIID, TFIIE, TFIIF, and TFIIH based on their chromatographical characteristics 
(reviewed in (278)).  RNA pol II by itself is unable to recognize promoters and initiate 
transcription.  The GTFs, through interactions with core promoter elements described above and 
other upstream activators, organize on the promoter to initiate transcription.   These factors are 
recruited in a stepwise fashion, beginning with TFIID binding first, followed by TFIIA, TFIIB, 
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TFIIF, which recruits RNA pol II, TFIIE, and TFIIH. 
TFIID is a large, multi-protein complex consisting of TBP and several TBP-associated 
factors (TAFs), which is highly conserved from yeast to humans (7).  TFIID recognizes the 
promoter through interactions with core promoter elements.  TBP binds to the TATA box in the 
minor groove of the DNA, significantly bending the DNA upon binding (194).  In addition, 
TAF1/TAF2 recognize the Inr sequence (28), TAF6/TAF9 recognize the downstream promoter 
element (DPE) (253), and TAF1 binds the down stream core element (DCE) (221).  These 
additional interactions with the core promoter allow TFIID to recognize both TATA-less and 
TATA-containing promoters.   
In addition to promoter recognition, TAFs are important for activated transcription. 
Purified TBP alone is able to reconstitute basal transcription in vitro but is unable to support 
activated transcription (22).  For activated transcription, the adddtion of TAFs in TFIID is 
required.  TAF1 exhibits several enzymatic activites, including histone acetyltransferase, kinase, 
and ubiquitin activating/conjugating activity, directed at both histones and other members of the 
cellular transcription machinery (reviewed in (292)).  In addition, several upstream activators 
have been shown to interact with various different TAFs to mediate their function.   
Binding of TFIID is stabilized by TFIIA and TFIIB (reviewed in (278)).  The C-terminus 
of TFIIB interacts with both TBP and the TFIIB-recognition element (BRE) on the core 
promoter.  These interactions stabilize the TBP:TFIIB:DNA ternary complex either in the 
presence or absence of TFIIA (195, 281).  The N-terminus of TFIIB facilitates the entrance of 
the TFIIF/RNA pol II complex via interactions with the RPB1 and RPB2 subunits of RNA pol II 
(23, 29, 100).   TFIIB also plays a role in positioning RNA pol II for proper transcription 
initiation.  TFIIA stabilizes binding of TFIID through interactions with TBP and DNA upstream 
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of the TATA box (63, 203).  TFIIA also inhibits TAF1-mediated repression of TBP binding to 
the TATA box (203).  This is borne out by the requirement for TFIIA for basal transcription 
driven by TFIID in reconstituted transcription systems.  Interestingly, TFIIA has been shown to 
be required for ICP4-mediated HSV E gene expression but dispensable for L gene expression in 
an Inr-dependent manner (312).   
The TFIID-TFIIA-TFIIB complex then recruits TFIIF/RNA pol II to the promoter via 
interactions between TFIIB and both TFIIF and RNA pol II (23, 29, 100).  TFIIF has multiple 
functions in the PIC, including stabilizing RNA pol II binding to the TFIID-TFIIB promoter 
complex, repressing spurious initiation through inhibition of RNA pol II binding to non-
promoter regions, and recruitment of TFIIE and TFIIH (reviewed in (278)).  TFIIF also 
facilitates in subsequent steps of transcription, including promoter clearance and elongation.   
RNA pol II is a large protein complex made up of 12 subunits, RPB1 to RPB12, that are 
highly conserved from yeast to humans with some sharing similarity with bacterial RNA 
polymerases.  X-ray crystallography has elucidated the structure of the RNA pol II enzyme, 
showing in part that the complex forms a clamp-like structure that closes on the DNA during 
transcription (43, 299).  A major site of RNA pol II regulation is the C-terminal domain (CTD) 
found in the largest subunit, RPB1 (reviewed in (59, 278)).  The CTD consists of a heptapeptide 
tandem repeat of tyrosine-serine-proline-threonine-serine-proline-serine (YSPTSPS) with 52 
repeats in humans, 42 times in Drosophila, and 26-29 times in yeast.  This region is heavily post-
translationally modified via phosphorylation at serines 2 and 5 and glycosylation of the serine or 
threonine residues.  The phosphorylation of serines 2 and 5 act as a marker indicating the stage 
of transcription.  As such, there are two general forms, RNA pol IIO, RNA pol IIA.  The IIA form 
represents the hypo- or unphosphorylated CTD and is generally involved in PIC formation and 
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initiation.  Serine 5 phosphorylation occurs at the promoter during the inititation and clearance 
phases.  Serine 2 is then phosphorylated during the elongation phase, thus constituting the 
hyperphosphorylated form IIO where both serine 5 and serine 2 is phosphorylated.  Several 
cellular kinases that target the CTD have been identified, including the TFIIH-associated CDK7, 
mediator-associated CDK8, and CDK9, which is associated with elongation factors.  
Interestingly, HSV infection induces an abberant form of phosphorylated RNA pol II, IIi, where 
only serine 5 is phosphorylated (228).   
 The final two GTFs, TFIIE and TFIIH, are important for promoter melting and initiation 
of transcription (116).  Experimental systems involving pre-melted templates do not require their 
presence. TFIIE aids in the recruitment and regulation of TFIIH.  TFIIE interacts with RNA pol 
II, TFIIB, and promoter DNA to facilitate binding (74, 75, 171, 201, 293, 310).  It also recruits 
TFIIH and augments its ATPase, DNA helicase, and CTD kinase activities (153, 199, 200, 251).  
Through these functions, TFIIH aids in initation of transcription through promoter melting and 
conversion of RNA pol II from its PIC form to a stable elongating form. 
1.5.3 Mediator 
Another large complex involved in nearly all cellular transcription is the Mediator complex.  It 
was initially described as a cofactor required for the activities of various activators, including 
thyroid receptor (TRAP complex), vitamin D receptor-interacting protein complex (DRIP), 
activator recruited complex (ARC) and Sp1 (CRSP) (reviewed in (278)).  In humans, two general 
forms have been characterized based on chromatographic properties: the large complex called 
Mediator P.5 and the small complex, Mediator P.85.  The larger complex corresponds to 
TRAP/SMCC and ARC/DRIP and contains a dissociable kinase module generally linked with 
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repression.  The smaller complex P.85, such as CRSP, lack this module.  Structural studies reveal 
a common organization of the different Mediator complexes that consist of a head, middle, and 
tail module.  The head module primarily interacts with RNA pol II and undergoes a dramatic 
conformational shift upon association with pol II.  The middle and tail modules also make some 
contact with RNA pol II but mostly are involved in interactions with various cellular activators 
(18, 27, 38).   
 The primary function of the Mediator complex is to serve as a bridge between activators 
and the GTFs and RNA pol II (129, 154, 276, 279).  Mediator alone can enhance both basal and 
activated transcription in in vitro reconstituted systems.  It does this mostly through interactions 
with RNA pol II and upstream activators.  Mediator can also enhance TBP binding to the TATA 
box and stabilize the promoter-bound scaffold complex, thus enhancing reinitiation of 
transcription from the same promoter. 
1.5.4 TAF-containing complexes 
In addition to TFIID, there are other large, TAF-containing complexes that are important for 
transcription.  These TAF-complexes, including TBP-free TAF-containing complex (TFTC), the 
PCAF/GCN5 complexes, the yeast Spt-Ada-Gcn5 acetlytransferase (SAGA) and its human 
homolog (STAGA), all lack TBP and can drive transcription from both TATA+ and TATA- 
promoters (reviewed in (192)).  Despite being made up of different subunits, these complexes do 
share a subset of TAFs including TAF6, -9, -10, and -12.  Similar to TFIID, these complexes all 
have HAT activity, and TFTC and TFIID form a similar clamp-like structure with varying 
number of lobes surrounding a solvent-accessible grove for DNA-binding.  These complexes can 
also recognize some core promoter elements through shared TAF subunits, and SAGA has been 
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shown to interact with and recruit TBP to some TATA+ promoters (291).  The similarities shared 
between TFIID and these TAF-containing complexes along with the observation that loss of 
TFIID-specific TAF1 function only results in a partial loss of global transcription suggest these 
complexes may play a similar role in promoter recognition and transcription as TFIID. 
1.6 CASCADE OF VIRAL GENE EXPRESSION 
The viral gene expression program proceeds as a tightly regulated cascade consisting of three 
broad stages called kinetic clases: the Immediate Early (IE, or ?), Early (E or ?), and Late (L or 
?)(figure 2)(112, 120, 121, 170, 211).  The stages are defined both by their temporal expression 
and their expression in the presence of various inhibitors.  The IE genes are the first class to be 
expressed, can be detected as early as 30 minutes post-infection, reach peak expression levels 
between 2 and 4 hours post-infection, and do not require prior viral protein synthesis for 
transcription (120, 121).  There are six IE proteins, including ICP0, ICP4, ICP22, ICP27, ICP47, 
and US1.5, whose orf is contained entirely within the ICP22 locus (33, 120, 211).  Five of the six 
IE proteins, ICP0, 4, 22, 27, and US1.5 coordinate the expression of the remaining classes of 
expression while ICP47 inhibits antigen presentation to CD8 T cells (47, 55, 172, 241).  
Accumulation of sufficient IE protein leads to the expression of E genes and the subsequent 
reduction in IE expression.   
The second class of genes, the E genes, reaches peak expression between four and six 
hours post-infection (120, 121).  These genes require de novo viral protein synthesis but reach 
maximal expression in the absence of viral DNA replication.  This class consists primarily of 
DNA replication machinery and modulators of nucleotide metabolism, including the viral DNA 
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polymerase (UL30), origin binding protein (UL9), ICP8, and thymidine kinase (tk) (236).  
Expression of E genes leads to the onset of DNA replication at around four hours post-infection 
and continuing as late as 15 hours post-infection (120, 121). 
 
Figure 2:  The temporal cascade of viral gene expression. 
Viral transcription can be divided into three temporal phases, Immediate early (blue), Early (green), and Late (red).  
The immediate early genes reach peak expression between 2 and 4 hours post-infection (hpi) and are involved in 
coordinating the expression of the remaining classes of genes.  The E genes are maximally expressed between 4 and 
6 hpi and encode the viral DNA replication machinery.  After sufficient E gene expression, viral DNA replication 
commences.   The Late genes require DNA replication for their expression and encode the structural components of 
the virus. 
 
The final class of genes, the L genes, is not expressed to maximal levels until after DNA 
replication begins (86, 124, 289, 295).  They can be subdivided into two groups, leaky late or ?1, 
which are expressed in low levels prior to DNA replication but require it for maximal expression 
(313), and true late or ?2, which are not expressed until after DNA replication commences.  This 
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class encodes proteins required for the assembly and egress of progeny virions as well as many 
of the tegument proteins.  Robust expression of late genes leads to production of detectable 
progeny virions by eight hours post-infection. This progeny production increases exponentially 
resulting in the eventual death of the host cell.   
Regulation of the viral gene expression cascade continues to require additional 
investigation; however, it is clear that the orderly expression of gene classes is mediated through 
the dynamic interaction between viral and cellular factors at both the transcriptional and 
translational level.  Accumulation of mRNA determines the pattern of expression and this 
accumulation is chiefly regulated at transcription initiation (289, 290).  Thus the initiation of 
transcription serves as a pivotal site of regulation. Each viral ORF is driven by its own promoter 
containing a TATA box that is recognized by the cellular transcription machinery (8, 41).  As 
such, viral promoters have many similarities with their cellular counterparts including other 
cellular promoter elements and binding sites for cellular transcription factors.  Each kinetic class 
has its own general promoter structure, which allows the viral and cellular transcription factors to 
either positively or negatively regulate each class (figure 3)(35, 119, 178, 273). 
The virus also alters the cellular environment to divert resources from expression of 
cellular to viral genes and to aid in the switch between different viral classes.  Entering with the 
infecting virion as part of the tegument, vhs is an endonuclease that indiscriminately degrades 
both cellular and viral mRNA species (147-149).  This serves to inhibit production of cellular 
proteins while viral mRNA translation continues due to their rapid and robust transcription.  The 
decreased RNA stability also allows for a tighter transition between viral temporal classes and 
underscores the role transcription rates play in determining gene expression.   
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Figure 3:  Schematic representation of representative Immediate Early, Early, and Late gene promoters. 
The cis-acting elements and their spatial arrangement are shown for the ICP4, tk, VP16, and gC promoters.  
Common to all HSV promoters is the TATA box, which serves as a major binding site for the cellular transcription 
machinery.  The number and arrangement of the cis-elements varies from promoter to promoter, wit h an overall 
trend of decreasing complexity from IE to L promoters. 
 
 
In addition to RNA stability, the virus also impedes RNA-splicing through the action of 
the viral IE protein ICP27 (105, 106).  This serves to repress the expression of intron-containing 
cellular genes while allowing expression of the generally intron-less viral genes to proceed.  
Indeed, there are only four lytically expressed viral genes that contain introns, and three of them, 
ICP0, ICP22, and ICP47 are IE genes that would be transcribed and spliced prior to ICP27’s 
inhibition (reviewed in (236)).   The virus also alters the transcription environment by altering 
histone modifications (96), phosphorylation of transcription factors (139) and RNA polymerase 
II (164), and the abundance and localization of the transcription machinery (223, 312), all in the 
pursuit of diverting cellular resources to maximize viral transcription and replication.  The 
 20 
regulation of the different classes as well as the contribution of specific viral proteins to the 
regulation will be discussed in detail in the following sections. 
1.6.1 Regulation of Immediate Early genes 
The IE genes are expressed within the first hour of infection making them the first class to be 
expressed (122, 123).  The promoter structure of the IE genes are the most complex of the three 
classes with binding sites for many cellular and viral factors (figure 3).  IE genes are expressed 
prior to viral protein synthesis and are dependent on cellular factors for efficient transcription.  A 
hallmark of the IE genes is the TAATGARAAT promoter element found upstream of the TATA 
box and is responsive to a complex consisting of viral VP16 and the cellular HCF and Oct-1 (13, 
166, 167).  The tegument protein VP16 enters the cell with the infecting virion and associates 
with HCF as it traffics into the nucleus (150, 151).  The VP16-HCF complex then interacts with 
Oct-1 at TAATGARAAT motifs to stimulate transcription (142, 144, 177).  VP16 contains a 
potent acidic transcription activation domain that interacts with several cellular factors to 
stimulate transcription (91, 243). These stimulating factors include members of the general 
transcription factors (87, 160, 275, 304), chromatin remodeling complexes (114), and the 
Mediator complex (306). In addition to the TAATGARAAT elements, IE promoters contain 
binding sites for other cellular transcription factors.  The GC box and CCAAT motif act as 
binding sites for Sp1 and CTF or NF1, respectively, that act in concert with VP16 to activate 
transcription (132).   
 The expression of IE genes peaks approximately two to three hours post-infection then 
tapers over time.  One of the contributing factors in this decrease is the IE protein ICP4.  ICP4 
inhibits activation through the cooperative formation of a stable, tripartite complex (TPC) with 
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TBP and TFIIB on promoters containing the high-affinity ICP4 binding site (145, 266).  The 
only IE promoter that contains a properly positioned ICP4 binding site is ICP4, itself.  It is 
unclear to what extent ICP4 participates in the repression of the other IE genes. However, 
deletion of ICP4 results in their overexpression.  This may due to a loss of a repressive function 
played by ICP4 or the loss of E gene expression.  ICP27’s interference in RNA splicing may also 
play a role in shutting down IE gene expression, albeit at a post-transcription initiation step.  As 
mentioned above, three IE genes contain introns and thus require the cellular splicing machinery 
for their expression. 
1.6.2 Regulation of Early genes 
Efficient expression of the E genes requires the IE proteins, especially ICP4.  E promoters retain 
many of the same binding sites for cellular factors as the IE promoters but lack the 
TAATGARAAT binding site thus delaying their activation.  E promoters do contain a TATA 
box and several upstream binding sites for Sp1 and other cellular transcription factors (132).  
These binding sites are not as numerous as on the IE promoters but still play an important role in 
E gene activation.  Sp1 is a common transcription factor that interacts with the general 
transcription factors, specifically TAF10 of TFIID (115, 277), and Mediator (239) to activate 
transcription.  ICP4 recruits general transcription factors to E promoters through non-specific 
DNA binding (26, 92). ICP4 binding is required at E promoters for efficient recruitment of both 
TBP and pol II (247).   
 E gene expression peaks between four and six hours post-infection and declines as robust 
DNA replication commences.  The mechanism of E gene transcriptional downregulation is not 
fully understood, but evidence suggests viral DNA replication and viral-induced changes in the 
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transcription machinery is involved.  Sp1 is phosphorylated at later times of infection, and this 
phosphorylation temporally corresponds to reduced E gene expression (139). The 
phosphorylated form of Sp1 harvested from infected cells retains efficient DNA-binding ability 
but exhibits reduced transactivation of the tk E promoter in vitro (139).  Viral DNA replication 
also links to repression of E genes, mainly through the observation that inhibitors to viral DNA 
replication lead to an over-expression of E genes (156).  These same inhibitors also partially 
block Sp1 phosphorylation suggesting a correlation between these observations (139).  HSV 
infection also induces a reduction in the general transcription factor (GTF) TFIIA at late times of 
infection (312).  Interestingly, TFIIA is required for efficient activation of E but not L genes, 
suggesting its loss may play a critical role in the switch from E to L expression. 
1.6.3 Regulation of Late genes 
The late genes are the last class to be expressed.  As mentioned previously, late genes require 
viral replication for maximal expression and can be divided into two groups based on the degree 
of dependence.  Low levels of leaky late genes can be detected prior to DNA replication while 
true late genes are entirely dependent on replication for expression (39, 120, 121, 313).  The 
foundation for the difference between the 2 subgroups is unclear. Inherent differences in late 
gene promoter strength, progressive dilution of inhibitors by continued DNA synthesis, or post-
replication changes in the genome could play a role.  The repressive mechanism appears to act at 
least in part at a post-preinitiation complex formation step, as recent evidence has shown the 
ICP4-dependent recruitment of TBP and RNA pol II to the gC promoter in the absence of DNA 
replication (247).  Therefore the locus of regulation of late gene transcription seems not to be 
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exclusively related to the binding of factors to the promoter, but also to later steps in 
transcription. 
The L promoters are the simplest of the three classes in that they contain very few if any 
upstream cis-acting sequences (figure 3) (118, 119).  Indeed, true late promoters usually have 
none while leaky late may have one or two binding sites for cellular activators (290, 295). These 
sites most likely explain their low levels of expression prior to DNA synthesis.  Instead of 
upstream sites, L promoters are dependent on cis-acting sites downstream of the TATA box and 
the non-specific DNA-binding of ICP4 for efficient expression.  These sites include the down 
stream activating sequence (DAS) and the Initiator element (Inr) (97, 98, 273, 298).    The DAS 
element is essential for the proper expression of some late genes (UL38) but not others (gC) (93, 
140).   
The Inr is a common cellular promoter element that is recognized by various cellular 
factors, including TAF1/2 of TFIID and TFII-I (28, 238, 263).  Efficient activation of gC 
requires an intact Inr element. As Inr is a known binding site for TAF1/2, and TAF1/2 are 
specific to the TFIID complex, the recruitment of TFIID to late promoters is critical for 
expression (93, 140).  Deletion of the Inr results in loss of gC expression by decreased TFIID 
binding and a corresponding decrease in the recruitment of TBP and RNA pol II to the promoter 
(247).  Inr deletion also results in a decrease in the amount of ICP4 bound to the promoter, 
suggesting ICP4 and TFIID binding may be cooperative, thus facilitating ICP4’s non-specific 
binding to DNA (247).  The presence of the Inr also alleviates the requirement of TFIIA for 
efficient transactivation.  This may be part of the mechanism that underlies the switch from E to 
L gene expression, as the amount of TFIIA is reduced at L times of infection. 
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1.7 IMMEDIATE EARLY VIRAL PROTEINS INVOLVED IN TRANSCRIPTION 
HSV encodes several proteins that are involved in transcription.  Two proteins, VP16 and vhs, 
are important in initiating the viral transcription program and were discussed earlier.  As 
mentioned above, the IE proteins’ primary role is to facilitate viral transcription. Four of five IE 
genes are involved at either transcription or post-transcription stages of gene expression.  The 
expression of these proteins serves to enhance viral replication by activating viral gene 
expression and inhibiting host processes. 
1.7.1 ICP0 
Despite playing a key role in several processes, ICP0 is considered non-essential in tissue culture 
with mutants being impaired for growth, especially at low MOIs (242).   ICP0 is a 110 kDa 
phosphoprotein that contains a RING finger domain with E3 ubiquitin ligase activity that is 
essential for ICP0 function (65, 66, 211, 212).  ICP0 has been shown to be a critical determinant 
of viral latency, playing key roles in both lytic replication and establishment of and reactivation 
from latency (24, 32, 107, 244).   
 ICP0 is considered a promiscuous transactivator due to its ability to activate expression in 
transient assays from a broad range of promoters with no sequence specificity (67, 84, 197).  
ICP0 facilitates lytic replication and the expression of all three classes of genes through 
increased transcription rates (25, 133, 246).  In transient expression assays, ICP0 and ICP4 
synergistically increase expression from responsive promoters to greater levels than either 
achieve individually (67, 197).  They have also been shown to interact, in vitro (309).  ICP0 
targets additional cellular processes to promote viral replication.   Early in infection, ICP0 co-
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localizes with and disrupts cellular ND-10 bodies (68, 169).  These structures contain several 
different cellular proteins that are involved in a variety of cellular functions.  ICP0 also inhibits 
the cellular DNA-damage response and the antiviral interferon response (60, 155, 206). 
1.7.2 ICP22 
ICP22 is also dispensable for viral replication in a cell-type specific manner.  It is a 68 kDa 
phosphoprotein that facilitates expression of a subset of late genes (249).  ICP22, in conjunction 
with UL13 protein kinase, induces the stabilization of cdc2 and the degradation of cyclins A and 
B (4).  Free cdc2 then interacts with UL42 to recruit topoisomerase IIa to newly synthesized viral 
DNA to aid in resolution of tangled concatemeric DNA and aid in L gene expression (5, 6).   
ICP22 and UL13 also phosphorylate the RNA pol II CTD to form the aberrantly phosphorylated 
form of RNA pol IIi found during HSV infection (164).  The effect of this phosphorylation is 
unclear but is thought to aid in diverting transcription from cellular to viral genes (228, 229). 
1.7.3 ICP27 
ICP27 is multifunctional 63 kDA protein that is required for viral replication.  ICP27 co-
localizes with ICP4 in viral replication compartments where it alters the cellular RNA splicing 
machinery, aids in the export of viral mRNA, and facilitates the function of both ICP0 and ICP4 
(180, 226, 245).  ICP27 is required for the efficient expression of a subset of E genes, 
specifically those involved in DNA replication, making it indirectly necessary for DNA 
replication (226, 241, 284).  It is also necessary for efficient expression of at least some L genes, 
both due to its role in promoting DNA replication and through direct activation of L gene 
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expression (131, 226, 227).  As mentioned earlier, ICP27 inhibits RNA splicing to the benefit of 
the mostly intronless viral genes (20, 106).  It also aids in the export from the nucleus of 
unspliced RNA (106, 248).  In addition, ICP27 effects the elongation, termination, and 
polyadenylation site selection during transcription through its interaction with the CTD of RNA 
pol II (103, 176, 179).   In cellular transcription, the processes of elongation, splicing, and 
polyadenlyation are linked both temporally and spatially through various protein interactions. 
Similar to cellular transcription where proteins involved in a specific stage of transcription 
regulate the recruitment and function of those proteins involved in other stages, ICP27 modulates 
the function and phosphoryation pattern of ICP4, and ICP4 and ICP27 have been shown to 
interact in vitro (204, 226, 245). 
1.7.4 ICP4 
ICP27 functions primarily in the post-transcription initiation phase while ICP4 activates 
transcription at the preinitation stage. ICP4 is the major regulator of viral transcription and is 
required for productive infection (47, 55, 217, 294).  It acts both as a transcriptional activator and 
repressor, activating E and L genes while repressing its own transcription (48, 67, 84, 86, 197, 
198, 224).  ICP4’s regulatory function is primarily through interactions with the cellular general 
transcription machinery at the promoter.  HSV-1 expressing nonfunctional mutants of ICP4 
exhibits an increased expression of IE genes while failing to express E or L, thus ICP4 is critical 
for the switch from IE to E and subsequently L gene expression (47, 55, 217). 
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1.7.4.1 ICP4 localization 
ICP4 can first be detected less than one hour post-infection in small, discreet foci lining the 
nuclear rim (42, 211).  These foci localize adjacent to ICP0 and ND-10 structures and contain 
one or more viral genomes (70).  As infection proceeds, a portion of these foci develop into 
replication compartments acting as sites of both viral transcription and DNA replication (269).  
As such, ICP4 co-localizes in these compartments with both viral and cellular factors involved in 
these processes, including TBP, RNA pol II, ICP27, ICP22, ICP8, and the viral DNA polymerase 
(69, 165, 223, 283).  At later times in infection, a proportion of ICP4 is found in the cytoplasm in 
an ICP27 dependent manner (314).  The majority of ICP4 staining, however, remains in the 
nucleus in replication compartments.  The function of the ICP4 found in the cytoplasm is unclear 
although, ICP4 is packaged in the viral tegument also in an ICP27 dependent manner (250, 308). 
1.7.4.2 ICP4 structure 
ICP4 is a large, structurally complex molecule that exists in cells as an elongated, 350 kDa 
homodimeric phosphoprotein (42, 184, 211, 257).  The IE3 locus, which encodes ICP4, is 
located in the US terminal repeats making two copies per genome (188).  The protein is 1298 
amino acids with a corresponding molecular weight of 175 kDa (42).  Due primarily to its 
heavily phosphorylated state, ICP4 presents as three different species on SDS-PAGE gels and as 
many as seven on 2-D gels (2, 73, 211, 296, 302).  In addition to phosphorylation, ICP4 exhibits 
several other post-translational modifications, including adenylation, guanlyation, and ADP-
ribsoylation (16, 17).  To date, however, the only modification that has been shown to effect 
ICP4 function is phosphorylation (12, 186, 205).  Gel filtration analysis has shown the ICP4 
molecule adopts an elongated structure with a Stokes radius of approximately 90 Å and an axial 
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ratio of 20 to 1, possibly allowing it to exert influence over long distances (184, 257).
 
Figure 4:  Functional domains of ICP4. 
The 1298 amino acid primary sequence of ICP4 is shown. Below the primary sequence, white boxes indicate regions 
of similarity between ICP4 and its VZV homolog IE62.  Colored boxes and text describe the various domains of 
ICP4 and their function. 
 
 
ICP4 has been divided into several discreet regions based on various functional properties 
(figure 4).  These functional domains correlate strongly with regions of significant amino acid 
similarity between ICP4 and its orthologs from other alpha-herpesvirus family members 
including pseudorabies virue IE180, VZV IE62, and the equine herpesvirus immediate-early 
protein (30, 174).  They include two transcriptional regulatory regions localized in the N- and C-
terminal regions separated by a dimerization domain, nuclear localization sequence (NLS), and a 
DNA-binding domain that contains a helix-turn-helix motif (49, 50, 81, 207, 208, 256).  The 
ability of ICP4 to bind DNA, dimerize, and localize to the nucleus all contribute to the functions 
attributed to its transcriptional regulatory domains. 
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1.7.4.3 The N-terminal regulatory domain of ICP4. 
The transcriptional regulatory domain found in the N-terminus of ICP4 spans amino acids 30-
210 and can perform many of the regulatory functions of ICP4.  A mutant termed n208 that is 
truncated at amino acid 774 and lacks the C-terminal regulatory domain retains the ability to 
repress its own transcription and transactivate a subset of E genes (50).  It does not, however, 
efficiently replicate its DNA, most likely due to its partial deficiency in E gene expression, or 
express L genes.  Deletions of both the transcriptional regulatory domains result in non-
functional mutants that are trans-dominant (257).  The N-terminal region has been shown to be 
important for ICP4’s formation of a tripartite complex with TBP and TFIIB at strong ICP4 
binding sites (145, 266).  TPC has been shown to be involved in ICP4-mediated repression (94, 
145).  In addition, this region is important for ICP4-mediated stabilization of TFIID on some 
viral promoters (92). 
1.7.4.4 Serine tract 
The polyserine tract found in the amino terminus of ICP4 is a conserved stretch of 24 residues, 
13 of which are serines.  It can be found in all of the neurotropic alpha-herpesviruses including 
HSV-1 and -2, VZV, pseudorabies virus, Marek’s disease virus, equine herpesvirus 1 and bovine 
herpesvirus 1 (30, 174).  It is heavily phosphorylated, mediates phosphorylation of other regions 
of ICP4, and plays a unique role in viral growth in neurons.   
 The serine tract also has homology to a small cellular protein, P15, which supports VP16 
activation during infection (12).  The serine tract has consensus sites for phosphorylation by the 
cellular kinases PKA, PKC, and casein kinase II (302, 303).  It is phosphorylated in vitro by 
PKA and PKC (302, 303).  Interestingly, deletion of the serine tract results in loss of 
phosphoryation not only of those residues that are deleted but also residues in other areas of 
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ICP4. This suggests phosphorylation of the serine tract leads to successive phosphorylation of 
other regions of ICP4 (302, 303).  Interestingly, deletion of the serine tract has only a small 
impact on viral growth in tissue culture and in the corneas of mice, but these viruses show 
significant impairment in growth in neurons.  This virus lacking the serine-tract immediately 
enters into a latent state in mouse trigeminal ganglia and reactivates much less efficiently (12). In 
neurons, lytic infection with this mutant virus is halted just prior to viral DNA synthesis with low 
levels of expression of IE genes and some E genes, and very low expression of some late genes 
(12).  This may be due to the reduced phosphorylation of the ICP4 mutant, considering the wild-
type virus exhibits similar growth deficiencies in PC12 cells that lack PKA.  This parallel 
indicates a potential role for PKA in viral replication through the phosphorylation of the serine-
tract of ICP4 (303).  Changes in the post-translational modifications may represent the difference 
in activity of this obviously vital region of ICP4. 
1.7.4.5 DNA binding  
ICP4 is both a sequence-specific and non-specific DNA binding protein, both abilities localizing 
to a region between amino acids 263 to 487 (207, 256).  This region is highly conserved between 
ICP4 and its VZV homolog IE62 and includes a predicted helix-turn-helix motif commonly 
found in DNA-binding proteins.  DNA-binding is required for both ICP4-mediated 
transactivation and repression although the requirement for binding is different.  Repression 
requires specific ICP4 binding sites at or near the start site of transcription whereas no specific 
binding site has been characterized for transactivation (94, 95, 145, 207, 208, 232, 256).   ICP4 
binds to the degenerate sequence RTCGTCNNYNYSG, where R is purine, Y is pyrimidine, S is 
C or G, and N is any base (72, 78).  For proper repression of a promoter, the ICP4 binding site 
must be present both in the correct orientation and in close proximity to the transcription 
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initiation site (145, 231, 232).   While there are ICP4 sites of varying strengths scattered 
throughout the genome, only a few promoters, LAT, ORF P, ORF O, and ICP4, have properly 
positioned sequences for efficient repression (94, 145, 185, 232). 
The role DNA-binding plays in ICP4-mediated transactivation is less clear.  Although no 
binding sites have been associated with transactivation, ICP4 mutants unable to bind DNA are 
also nearly universally unable to activate transcription (35, 61, 64, 102, 265).  In addition, 
recruitment of TBP and RNA pol II to viral promoters requires ICP4 to also be present, showing 
the importance of DNA-binding (247).    Mutants have been developed, however, that lack 
efficient DNA-binding but retain some level of transactivation efficiency (128, 209, 254).  
Interpretation of these results is complicated by ICP4’s sequence and non-sequence specific 
DNA-binding. These mutants were unable to bind to the ICP4 consensus sequence but may 
retain the ability to non-specifically bind DNA with low affinity.  The C-terminus of ICP4 also 
mediates ICP4 multimerization on DNA and the cooperative recruitment of ICP4 and TFIID to 
promoters containing the Inr element, both of which may function to increase its overall affinity 
for DNA (146, 247).  This cooperative recruitment may serve to increase ICP4’s affinity for 
DNA, enriching non-specific ICP4 binding to promoter regions. 
1.7.4.6 Nuclear localization 
ICP4 localizes primarily to the nucleus during infection.  This ability comes from the ICP4 
nuclear localization sequence (NLS) between aa 723 and 732 (50, 207).  This NLS has 
similarities to the SV40 virus large T-antigen protein, and thus may operate in a similar fashion.  
The large T-antigen NLS is recognized by the importin 58/97 complex, which targets proteins to 
the nuclear pore complex (88, 89, 134).    At late times of infection, a fraction of the total cell 
ICP4 localizes to the cytoplasm.  The mechanism for ICP4’s retention in the cytoplasm is 
 32 
unclear.  The VZV homolog IE62 displays a similar though more dramatic localization pattern 
with a higher proportion localizing to the cytoplasm in late times of infection.  Interestingly, 
IE62’s localization is regulated by a phosphorylation event near its NLS by the viral kinase 
Orf66 (62). 
1.7.4.7 The C-terminal domain 
The C-terminus of ICP4 contains the largest region of homology with ICP4 orthologs.  Despite 
the extensive similarity, truncation mutants that lack the last 500 amino acids retain all the 
functions associated with ICP4, including DNA-binding and transcription repression and 
activation (50).  The truncation mutants are defective for growth, however, due to deficient DNA 
replication and L gene expression.   In regards to L gene expression, the C-terminus has been 
shown to interact with TAF1 of TFIID, an interaction important for efficient activation of the 
Inr-containing L genes (26).  This interaction, and possibly the multimerization of ICP4 on DNA 
also attributed to the C-terminus, is important for the recruitment of not only TFIID but also 
ICP4 to L, but not E, promoters (247).  Interestingly, some C-terminus mutants show 
temperature sensitive loss of ICP4 function.  This suggests the c-terminus plays a role in global 
ICP4 protein folding.  In addition, some temperature sensitive mutants retain DNA-binding and 
transactivation but lack the repression function generally attributed to the N-terminus.  This 
could also be due to defects in protein folding however, the retention of DNA-binding and 
transactivation suggests otherwise.  The C-terminus is clearly required for efficient viral 
replication and may mediate intra-molecular interactions to mediate ICP4’s full function (37, 46, 
55, 209, 219). 
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1.7.4.8 ICP4-mediated transactivation and repression 
ICP4 is the major activator of early and late genes during HSV-1 lytic infection.  It transactivates 
expression at the promoter by both recruiting the cellular transcription machinery to the promoter 
and stabilizing their binding (26, 92).   Although ICP4 activates both E and L genes, it does so 
through different mechanisms.  Mutational analysis of ICP4 has shown that both its N- and C-
terminal regulatory domains are important in transactivation; although each plays a different role 
(12, 26, 92).  Expression of E genes requires primarily the N-terminal domain while efficient 
expression of L genes requires the C-terminus.   
Transactivation functions via the GTF TFIID (26, 92).  TFIID, itself, is a multi-protein 
complex containing the TATA-binding protein (TBP) and several additional subunits known as 
TBP associated factors (TAFs) (7, 101).  This complex serves as the first GTF recruited to the 
promoter, and facilitates the formation of the pre-initation complex (202).  Studies of TFIID and 
ICP4 interactions show that the C-terminus of ICP4 specifically interacts with the TAF1 subunit 
and facilitates TFIID binding to the TATA box (26, 92). TAF1 has been shown to be important 
in facilitating TFIID interaction with Inr elements (286).  Although ICP4 can efficiently activate 
transcription with only a TATA box, in vitro transcription reactions using the late gene gC 
promoter show that the presence of an Inr sequence in the promoter greatly enhances 
transcription (93). The known interactions of ICP4 and the TFIID complex coupled with the 
observation that the TATA box and Inr sequence are the only cis-acting elements required for 
efficient activation of gC in vitro, underscore ICP4’s role as the major transcriptional activator of 
late genes (93, 140).   
As in transactivation, interactions with both DNA and the transcriptional machinery are 
required for efficient repression (145). A consensus ICP4 binding site located proximally to the 
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start site of transcription is necessary for efficient repression (145).  This presents a distinct 
difference between ICP4 repression and transactivation given that transactivation appears to 
require no specific ICP4 DNA binding site.  In vitro transcription assays show that ICP4 binding 
to its consensus site specifically represses activated transcription to basal levels.  Because basal 
transcription is achieved, ICP4 does not simply exclude the binding of GTFs, indicating possible 
protein interactions may also be involved in transcriptional repression (94, 95).  Gel 
electromobility shift assays using the ICP4 promoter show that ICP4 forms a tripartite complex 
(TPC) with TFIIB and TBP.  The presence of all three proteins greatly increases the affinity of 
ICP4 and TBP for DNA (266).  Additionally, ICP4’s ability to form this TPC correlates with its 
ability to repress activated expression from its own promoter (145, 266).  Thus, the process of 
ICP4-mediated repression requires DNA binding to consensus ICP4-binding sequences and 
interactions with TFIIB and TBP.   
The ability to form TPCs and repress transcription has been localized to the N-terminal 
domain.   A truncation mutant lacking the entire carboxy-terminus, n208, still exhibits efficient 
binding to and repression of transcription from the ICP4 promoter (49, 256).  Interestingly, 
smaller, temperature sensitive mutants in the c-terminus lose the ability to repress transcription 
but retain both the ability to bind ICP4 consensus sites and activate transcription from E 
promoters (37).  This implies there may be some cooperativity between the N- and C-terminal 
regulatory domains. 
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2.0  RATIONALE 
HSV gene expression proceeds in a highly regulated cascade that is mediated through 
interactions between viral and cellular factors.  ICP4 is required for the proper expression of all 
three classes of viral genes, making it the major transcriptional regulator of HSV transcription 
(47, 55, 217, 294).  ICP4’s role in both E and L gene expression and the significant difference 
between E and L promoter structures suggest ICP4 must be able to activate transcription in 
diverse environments.  In addition, HSV has been shown to alter the makeup of the cellular 
transcription machinery during the course of infection (77, 139, 229, 312).  Thus, regulation of 
global transcription in an infected cell and the subsequent cascade of viral gene expression are 
orchestrated by the complex interaction between a virally induced, evolving cellular transcription 
milieu, specifically influenced by ICP4 and other viral proteins.  
ICP4’s large size and complex structure may facilitate its role at diverse promoters and in 
changing environments, providing large surfaces for interactions with cellular and viral proteins 
to orchestrate the gene expression cascade. There are several regions of ICP4 that are conserved 
amongst other alpha-herpesvirus (30, 174).  These regions correspond to functional domains of 
ICP4 that are necessary for its activity, including the NLS and DNA-binding domains.  Of the 
two broad transcriptional regulatory domains, the C-terminus is the much more highly 
conserved. This conservation exists despite the fact that the N-terminal domain exhibits both 
transactivation and repression while the C-terminal domain is involved exclusively in 
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transactivation.  Interestingly, small temperature sensitive mutations in the C-terminus can 
abrogate ICP4 function, including those functions attributed to the N-terminus (37, 46, 55, 209, 
219).  This suggests that the C-terminus plays a role in the function of the N-terminus or on 
global ICP4 folding.  The fact that these mutants retain the ability to bind DNA suggests it is the 
former.   
The sole area of partial homology within the N-terminal domain with IE62 is a conserved 
serine tract.  Mutants lacking this region exhibit reduced viral replication in tissue culture and 
specifically show impaired growth in neurons (12).  Deletion mutants that lack the serine tract as 
well as additional sequences do show reduced transactivation in transient transfection assays 
using a CAT reporter construct driven by the tk promoter (256).  Additional studies fusing ICP4 
sequences to the GAL4 DNA-binding domain, thus separating the ICP4 transactivation and 
DNA-binding, showed that sequences between aa 97-109 may be important for activation (305).   
Taken together, the transactivation domains of ICP4 appear to not be simple linear stretches of 
primary sequence but more likely a complex tertiary structure that forms surfaces for interactions 
with the transcription machinery.    
ICP4 interacts with the general transcription machinery to recruit and stabilize the PIC at 
the promoter. This function is through contacts with TFIID (26, 92).  It also forms TPC with 
TBP and TFIIB on the DNA to exert a suppressive effect on transcription (145, 266).  In addition 
to the cellular transcription machinery, ICP4 has been shown to interact in vitro with ICP0 and 
ICP27 as well as with the cellular L22 in a yeast two-hybrid screen (158, 204, 309). 
As discussed above, ICP4 is a large protein with complicated structural domains. It 
functions to activate a diverse set of promoters in a changing cellular environment. The evolution 
from IE to E to L gene expression has been extensively studied and is partly due to changing 
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availability of cellular factors. The changing cellular mileu likely leads to changing interactions 
of ICP4 and GTF through the course of IE to E to L gene expression. The complexity of the 
ICP4 functional domains and the extensive role ICP4 plays in the regulation of the cascade of 
gene expression leads us to hypothesize that ICP4’s transcriptional regulatory domains form a 
complex tertiary structure that acts as a platform to mediate multiple protein-protein contacts 
with a diverse set of cellular protein complexes.  This would allow ICP4 to activate transcription 
from a diverse set of promoters while employing different cellular protein complexes.   
 
The goals of this study were to  
1) Characterize the N-terminal transcriptional regulatory domains that are necessary 
for ICP4 function and  
2) Identify the proteins that interact with ICP4 during infection.   
 
To characterize the functional domains, mutant viruses that express ICP4 deletion 
mutants with loss of the N-terminal transcription domain were made.  The d3-8 virus expresses 
an ICP4 molecule that lacks aa 30-142, which include the 90-110 region mentioned above, and 
the d8-10 mutant lacks aa 143-210.   In addition, the regions in the C-terminus of ICP4 have 
been shown to be important for functions attributed to the N-terminal regulatory domain.  With 
this in mind, the deletion mutants above were made in two forms.  The d3-8 and d8-10 which 
express the deletions in the context of full length ICP4 and nd3-8 and nd8-10 which contain a 
stop codon at aa 774.  These deletion-truncation mutants lack not only the specified deletion but 
also the C-terminus of ICP4. This allows for the examination of the separate and combined 
contributions of the N- and C-terminal transactivation domains of ICP4. These comparisons are 
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accomplished through metabolic protein labeling to assess protein expression and northern blot 
analysis to investigate accumulation of specific viral mRNA transcripts representative of the 
three classes of gene expression.  Viral growth curves assessed the effect these mutations have 
on viral growth while DNA-binding studies ensure any effect on regulation is due directly to the 
regulatoy domains and not to changes in DNA-binding affinity.  These viruses express the 
mutant ICP4 in the context of infection and allow for the study of ICP4 function in its native 
context.      
Tandem affinity purification (TAP) was used to investigate further the protein 
interactions made by ICP4 during infection.  TAP is a method of isolating protein complexes 
from the cell and has been used successfully to characterize several large protein complexes.  
Again, it is important to study ICP4 function in the context of infection, thus a virus that 
expresses an N-terminally TAP-tagged ICP4 will be developed.  Mass Spectrometry (MS) and 
western blot analysis will be used to characterize ICP4-containing protein complexes isolated by 
TAP.  Immunofluorescence will be used to verify colocalization between ICP4 and potential 
binding partners in vivo.  Finally, because ICP4 functions at promoters to recruit and stabilize 
PICs, chromatin immunoprecipitation (ChIP) studies were performed to investigate whether 
potential interactors are specifically recruited to viral promoters, in vivo. 
In addition to gaining a better understanding of the molecular biology of a ubiquitous 
human pathogen, this study will also help to understand the basic process of cellular 
transcription.  HSV provides a unique model system to study how different promoter elements 
respond to a changing cellular transcription mileu.  Studying the role ICP4 plays in activating or 
repressing the different viral promoters in the context of changing GTFs provides an 
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understanding of how the activity of cellular transcription factors can be modulated based on 
cellular conditions. 
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3.0  ROLE OF THE AMINO-TERMINAL SEQUENCES OF HSV-1 ICP4 IN 
TRANSCRIPTIONAL ACTIVATION AND REPRESSION 
3.1 ABSTRACT 
Herpes simplex virus type 1 (HSV-1) infected cell polypeptide 4 (ICP4) is a critical regulator of 
viral gene expression that is required for productive infection.  Depending on the promoter 
structure, ICP4 has been shown to act as both an activator and repressor of viral genes through 
interactions with both DNA and cellular general transcription factors including TATA-binding 
protein (TBP), TFIIB, and TFIID.  Although it has been shown that a region in the amino-
terminus of ICP4 corresponding to aa 30-210 is necessary for appropriate transactivation and 
repression of viral genes, specific domains responsible for these activities remain 
uncharacterized. We hypothesize that the transactivation and repression activities attributed to 
the amino-terminus of ICP4 are a result of or are regulated by discreet functional domains found 
in the amino-terminus. In this study, we use a combination of deletion and truncation mutants of 
HSV-1 ICP4 to isolate the transactivation and repression functional domains of the N-terminus.  
Using growth curve analysis, 35S-methionine-labeled protein SDS-PAGE, and northern blot 
analysis we show that while deletion of either aa 30-142 or 142-210 reduces ICP4 function, loss 
of aa 30-142 is more detrimental.  We also show the reduced transactivation efficiency of these 
mutants is not due to a corresponding reduction in DNA-binding.  Furthermore, the 
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transactivation deficient mutant still retains the ability to form tripartite complexes with TBP and 
TFIIB on DNA, a function necessary for efficient repression as shown by electromobility shift 
assays using purified protein.  Our results suggest that the transactivation and repression 
functions of ICP4 are indeed mediated by separate mechanisms and that ICP4’s transcriptional 
regulatory function may not be a discrete linear array of amino acids, or a domain, as with many 
other transcription factors. 
3.2 INTRODUCTION 
The immediate early protein of HSV-1, the infected cell polypeptide 4 (ICP4), is the major 
regulator of viral transcription and is required for productive infection (47, 55, 217, 294).  It acts 
both as a transcriptional activator and repressor, activating E and L genes while repressing its 
own transcription (48, 67, 84, 86, 197, 198, 224).  HSV-1 expressing nonfunctional mutants of 
ICP4 exhibit an increased expression of IE genes while failing to express E or L, thus ICP4 is 
critical for the switch from IE to E and subsequently L gene expression (47, 55, 217). 
ICP4 is a large, structurally complex molecule that exists in cells as an elongated, 350 
kDa homodimeric phosphoprotein (42, 184, 211, 257).  ICP4 binds DNA both non-specifically 
and specifically to the consensus sequence ATCGTCNNNNYCGRC where R = purine, Y = 
pyrimidine, and N = any base (72, 78).  DNA-binding is required for ICP4-mediated 
transactivation although specific ICP4-binding sites have not been demonstrated (35, 61, 64, 102, 
265).  Binding to strong sites at or near the start site of transcription associated with repression 
(94, 95, 145, 207, 208, 232, 256).  The significance of this disparity is unclear. 
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ICP4 regulates transcription through interactions with DNA and a variety of the cellular 
general transcription factors (GTFs). All HSV-1 genes are controlled by their own promoter and 
transcribed by the cellular RNA polymerase II (RNA pol II) transcription machinery (8, 41, 290). 
Regulation of viral gene expression is achieved through cellular and/or viral cis-acting elements 
found in the promoter structures of each class of genes as well as viral and cellular trans-acting 
proteins (64, 83, 120, 139, 290). The complexity of the promoter structures and their dependence 
on trans-acting cellular factors for activation decreases as infection proceeds with a 
corresponding increase in dependence on viral factors (290).  
ICP4 has been shown to stabilize the formation of preinitiation complexes (PICs) on viral 
promoters in vitro via enhancement of TFIID binding to the TATA box and to directly interact in 
vitro with both TBP and TAF1 of the TFIID complex (26, 92). In addition, ICP4 cooperatively 
forms a stable, tripartite complex (TPC) in vitro with TBP and TFIIB on promoters containing 
the ICP4 binding site (145, 266).  The formation of the TPC localizes to regions of ICP4 that are 
also required for efficient repression of activated transcription suggesting the TPC has a 
suppressive effect on promoters (94, 145).  ICP4 interaction with TBP and TFIIB specifically 
inhibits activated transcription at a step prior to elongation while allowing basal transcription to 
proceed implying it does not simply preclude binding of the PIC to the promoter (95).  This 
suggests ICP4 interferes with the action of activators through formation of TPCs to negatively 
regulate transcription from these promoters.   Thus, ICP4 mediates both positive and negative 
transcriptional regulation through complex interactions with DNA and several members of the 
cellular transcriptional machinery.   
In order to better determine how ICP4 regulates transcription, several studies have been 
performed to try to isolate and characterize the specific functional domains of ICP4. Several 
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functional domains have been described including two transcriptional regulatory regions 
localized in the N- and C-terminal regions separated by a dimerization domain, nuclear 
localization sequence, and a DNA-binding domain that contains a helix-turn-helix motif (49, 50, 
81, 207, 208, 256). These functional domains correlate strongly with regions of significant amino 
acid similarity between ICP4 and its orthologs from other alpha-herpesvirus family members 
(174). Interestingly, truncation mutants that lack the C-terminal transactivation domain retain 
autoregulation as well as transactivation of viral genes, albeit to a reduced level (26, 49, 50).  
These mutants are lacking, however, efficient L gene expression and thus show significant 
growth deficiency (50).   
The broad transcriptional regulatory domain found between aa 30-210 of the N-terminus 
of ICP4 exhibits both transactivation and autoregulation function. In order to more fully 
characterize these activities, viruses that express deletion and truncation mutants of the ICP4 N-
terminal transcriptional regulatory domain were developed.  This study examines the 
contributions of the N-terminal regulatory domain in the presence and absence of the C-terminal 
region of ICP4. It utilizes viruses that express mutant ICP4 in the context of infection and more 
directly studies gene expression via in vivo and in vitro methods at both the protein and mRNA 
levels.  In addition, the DNA-binding and tripartite complex formation of the mutant ICP4 
molecules were also studied. 
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3.3 MATERIALS AND METHODS 
3.3.1 Cells and viruses 
Vero and E5 cell lines were maintained by standard procedures.  E5 cells were derived from vero 
cells and express complementing levels of ICP4 (47, 49).  The HSV-1 wildtype strain, KOS, was 
propagated in vero cells while the ICP4 mutant viruses n12, n208 (50), nd3-8, d3-8, nd8-10, and 
d8-10 (50, 256, 266) were propagated on E5 cells.  Viral growth curves were performed on vero 
cells for all viruses. 5 x 105 cells were infected on ice with KOS or mutant HSV-1 at an MOI of 
5.  Virus was allowed to adsorb for 1 hour on ice, then cells were washed twice with cold Tris-
buffered saline (TBS) containing 0.25 mM Tricine, 137 mM NaCl, 5 mM KCl, 0.5 mM MgCl2, 
and 0.68 mM CaCl2, pH 7.35.  The infection was allowed to proceed at 37
oC for 2, 4, 8, 12, 24, 
or 36 hours as indicated.  Cells were then scraped into the media, freeze-thawed twice, and 
sonicated.  Virus was titered on E5 cells via plaque assay. 
3.3.2 
35
S-methionine peptide labeling 
Confluent monolayers of 5 x 105 Vero cells were infected in the presence or absence of 400 
ug/ml phosphonoacetic acid (PAA; Lancaster Synthesis, Inc) with either KOS or mutant HSV-1 
at an MOI of 10.  The infection was allowed to proceed in DMEM media either with or without 
400 ug/ml PAA for 6 or 12 hours at 37oC.  After 5 or 11 hours, the cells were washed once with 
warm TBS, then incubated with 1 ml warm TBS containing 50 uCi 35S-methionine for 1 hour at 
37oC.  Cells were then washed with cold TBS containing 0.1 mM N?-p-tosyl-L-lysine 
chloromethyl ketone (TLCK) and scraped into 0.2 ml 2x Laemmlli Sample buffer (BioRad).  
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Samples were boiled for five minutes, and the proteins were separated via SDS-PAGE.  The gel 
was dried and exposed to Hyperfilm (Amersham) to visualize the radiolabeled proteins.  
3.3.3 Southern blot analysis 
2 x 105 E5 cells were infected with virus and allowed to grow at 37oC until extensive CPE was 
observed.  Cells were then freeze-thawed twice and then centrifuged at 12,500 rpm for 15 min.  
Pellets were washed once in cold TBS and repelleted as above.  Pellets were resuspended in TE 
containing 0.6% SDS and 200 ug proteinase K (Roche) and incubated overnight at 37oC.  DNA 
was extracted twice in a phenol:chlorofom:isoamyl alcohol (25:24:1) mixture, followed by 1 
volume chloroform:isoamyl alcohol (24:1).  DNA was then precipitated in ethanol, pelleted, and 
washed with 70% ethanol.  Pellets were dried and resuspended in TE.  Samples were then double 
digested with BamH1 and PstI overnight at 37oC, loaded onto a 1.2% TBE-agarose gel, and 
separated overnight at 70 volts.  The samples were analyzed via Southern blot as described 
previously (244). The radiolabeled probe was made with the Nick Translation system 
(Invitrogen) following manufacturer’s protocol using 0.5 ug of the template pKBY containing 
the BamH1-Y fragment that contains part of the HSV-1 ICP4 gene and 5 ?l each of [?-32P]dCTP 
and [?-32P]dGTP.  The unincorporated nucleotides were removed using Centricep columns 
(Princeton Separations) as per the manufacturers protocol.  The membrane was then exposed to 
Hyperfilm. 
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3.3.4 Northern blot analysis 
5x106 vero cells were infected with wildtype or mutant HSV-1 at MOI of 10 in the presence or 
absence of 400 ?g/ml PAA.  6 or 12 hours post-infection, total RNA was harvested using 
Ultraspec RNA Isolation System (Biotecx Laboratories) following manufacturer’s protocol.  
RNA was quantified using Ribogreen RNA Quantitation (Invitrogen) per manufacturers 
specifications and a Storm 840 (Molecular Dynamics) using the Scanner Control version 4.1 and 
ImageQuant version 1.2 software (Molecular Dynamics).  20 ug of each RNA sample was loaded 
onto a 1.3% formaldehyde-agarose gel and separated at 50 volts overnight and assayed via 
Northern blot as described previously (126).  The radiolabeled probe was made with the Nick 
Translation system (Invitrogen) following manufacturer’s protocol using 0.5 ug template pKBY 
BamH1-Y fragment (ICP4) (245), pw3?HS8 (ICP0) (49), pLSWT (tk) (127), and pSXgC (gC) 
(140) and 5 ul each of [?-32P]dCTP and [?-32P]dGTP.  The unincorporated nucleotides were 
removed using Centricep columns (Princeton Separations) as per the manufacturers protocol.  
The membrane was then exposed to Hyperfilm. 
3.3.5 DNA-binding studies 
The ability of the ICP4 mutants to bind DNA was assayed via electromobility shift assay using 
whole cell protein extracts.  1 x 106 vero cells were infected with the indicated virus at an MOI of 
10.  Six hours post-infection, the cells were washed twice with cold TBS containing 0.1 mM 
TLCK, then scraped into 1 ml TBS with 0.1 mM TLCK and centrifuged at 12,500 rpm for 1 
minute.  The cell pellet was resuspended in 50 μl lysis buffer containing 50 mM Tris-HCl pH 
8.0, 500 mM NaCl, 2% NP-40, and 0.1 mM TLCK and incubated on ice for 30 minutes.  The 
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lysate was clarified via centrifugation at 12,500 rpm for 15 minutes. The supernatant was then 
used in electromobility shift assays as described previously (128).  The probe used was a ?32P-
ATP end-labeled EcoRI-BamHI fragment from the P4 plasmid.  This fragment spans sequences 
from -108 to +27 of the ICP4 promoter relative to the transcription initiation site and includes the 
TATA box and the ICP4 binding site (145).   
The ability of the ICP4 to form tripartite complexes with TBP and TFIIB was assayed via 
electromoblity shift assays with purified ICP4, TBP, and TFIIB.  Wildtype, n208, nd3-8, and d3-
8 ICP4 was purified from infected vero cells as described previously (128).  Recombinant TBP 
and TFIIB was purified as previously described (99, 135, 266).  15 ng ICP4, 60 ng TBP, and 500 
ng TFIIB were incubated with the labeled probe detailed above, as described previously (266).  
The binding reactions were then resolved in a native, 4% polyacrylamide gel at 200 V for 2 
hours.  The gel was dried and exposed to Hyperfilm. 
3.3.6 Western blot analysis 
5 x 105 vero cells were infected with the indicated virus at an MOI of 10.  The infection was 
allowed to proceed at 37oC for 6 hours.  The cells were washed in cold TBS containing 0.1 mM 
TLCK and then scraped into 0.2 ml 2x Laemmlli Sample buffer.  Samples were boiled for five 
minutes, separated via SDS-PAGE and analyzed via Western blot as previously described (255).  
The primary antibody used was a 1:5000 dilution of N15, a rabbit polyclonal specific to the N-
terminus of ICP4 as previously characterized (255) in 50 mM Tris, pH 7.5, 150 mM NaCl, and 
0.05% Tween-20 (TBS-T) and 1% milk.  The secondary antibody used was a 1:5000 dilution of 
an anti-rabbit polyclonal IgG-HRP conjugate (Promega) in TBS-T.  Bound antibody was 
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visualized using the ECL Plus Western Blotting Detection System (Amersham) per 
manufacturer’s protocol. 
3.4 RESULTS 
ICP4 is a critical regulator of HSV-1 gene expression, acting to both repress and activate viral 
genes. Despite expansive study, the mechanism of this regulation and the functional domains 
responsible are not fully understood.  Studies of the ICP4 molecule have elucidated two broad 
transcriptional regulatory domains: a large C-terminal domain that is involved in transactivation 
and a second N-terminal domain that both activates and represses transcription (figure 5)(50, 
256). The mutants used in this study were chosen to dissect the N-terminal regulatory domain 
with and without the C-terminal domain while leaving the other domains necessary for ICP4’s 
function intact.  In addition to the transcriptional regulatory domains between aa 30-210 and the 
C-terminus, ICP4 contains a DNA-binding domain between aa 263-487 and nuclear localization 
sequence at aa 723-732 (figure 5A)(208, 256).  Two broad deletions that span the N-terminal 
regulatory domain were made, the 3-8 and 8-10 deletions (figure 5B).  The 3-8 region spans 
amino acids 30-142 while the 8-10 spans 143-210.  These deletions were made in the context of 
either full length (d3-8, d8-10) or a C-terminal truncation at amino acid 774 (nd3-8, nd8-10).  
The mutant virus n12 expresses a mutant of ICP4 truncated at aa 251 which lacks the DNA-
binding domain making the peptide a non-functional negative control.   KOS serves as the 
wildtype form of ICP4, exhibiting full regulatory function, and n208, a virus that expresses the 
C-terminal truncation at aa 774 acts as a positive control for the regulatory function of the N-
terminal domain independent of the C-terminus. We studied the global viral gene expression 
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profile of these mutant viruses at the protein level as well as at the mRNA level of viral genes 
representative of IE, E, and L genes.  Because DNA-binding is required for ICP4’s regulatory 
function, the DNA-binding ability of the mutant ICP4 molecules was assessed as well as the 
ability to form tripartite complexes with TBP and TFIIB on DNA. 
 
 
Figure 5:  Structural schematic of the deletion and truncation mutants used in this study. 
A) The primary sequence and various functional domains of ICP4 are shown.  B) The expressed products of the 
deletion and nonsense mutants used in this study are shown.  KOS and n12 were used as a positive control and 
negative control for ICP4 function.  The n208 mutant was used to study the transcriptional regulatory activity of the 
N-terminus independently of the contributions of the C-terminus. 
 
3.4.1 Characterization of mutant ICP4 
The construction of the mutants used in this study has been described previously (49, 50, 256, 
266).  The approach taken to make the deletion mutants added a unique PstI restriction site at the 
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site of the deletion (figure 6A).  The KOS, n12, and n208 viruses do not contain deletions and 
thus contain the full-length 1.84 kb BamHI Y fragment.  The nd3-8 and d3-8 viruses share a 
common deletion of aa 30-142 resulting in a shortened 1.5 kb BamHI Y fragment that contains a 
PstI restriction site dividing it into two fragments of approximately 0.37 and 1.13 kb.   The nd8-
10 and d8-10 share a common deletion of aa 142-210 resulting in a 1.64 kb BamHI Y fragment 
with a PstI restriction site, resulting in two fragments of 0.70 and 0.94 kb.  The presence and 
position of the novel PstI site was confirmed via Southern blot (figure 6B).  Total DNA was 
harvested from infected vero cells and digested with BamH1 to isolate the BamHI Y fragment as 
well as PstI to test for the deletion.  The digested DNA was separated on an agarose gel and 
visualized via Southern blot using a probe specific for the BamHI Y fragment.  All of the viruses 
exhibited the expected fragment sizes indicating the appropriate genetic structure of the 
respective ICP4 genes (figure 6B).  In order to ensure proper expression and size of the ICP4 
molecules produced, whole cell lysates of infected cells were prepared and submitted to western 
blotting.  5 x 105 vero cells were infected with the indicated virus at an MOI of 10.  6 hpi, the 
cells were scraped into 2x Laemmli sample buffer and analyzed via western blot using the n15 
polyclonal antibody specific to the N-terminal 774 amino acids of ICP4.  The KOS virus 
expresses full length ICP4 of 175 kDa, while the truncation mutants, n12 and n208, express ICP4 
peptides of 41 and 96 kDa, respectively (figure 6C).  The d3-8 virus has a deletion between aa 
30-142 resulting in a predicted mass of approximately 160 kDa while nd3-8 has the same 
deletion but with the additional c-terminal truncation making an 81 kDa peptide.  The d8-10 and 
nd8-10 share a deletion of aa 142-210 in the context of full length ICP4 or the c-terminal 
truncation resulting in a predicted mass of 160 kDa and 85 kDa, respectively.  All the viruses 
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expressed a single band of the expected molecular weight indicating the proper expression and 
homologous nature of the mutants (figure 6C). 
 
 
Figure 6:  Characterization of the deletion and nonsense mutants used in this study. 
A) The ICP4 ORF is described (bold arrow) in the context of the surrounding HSV-1 DNA.  The BamHI Y fragment 
is shown in more detail, indicating the inserted Pst I site in the mutant viruses and the expected size of the BamHI-
PstI digestion fragments.  B) Viral genomic DNA was harvested from vero cells infected with either wildtype or 
mutant virus and digested with BamHI and PstI.  The resulting fragments separated via electrophoresis and detected 
via Southern blot with a radiolabeled probe specific for the ICP4 orf.  C) The expression and relative size of the 
ICP4 proteins expressed by the mutant viruses was analyzed via western blot.  Vero cells were infected with the 
indicated virus at an MOI of 10.  Total protein was harvested 6 hours post-infection and subjected to western blot 
analysis using a polyclonal antibody specific to the N-terminus of ICP4. 
 
Because ICP4 is required for viral growth, mutant viruses that express functionally 
impaired ICP4 have distinct growth phenotypes.  Viral growth curves were performed to assess 
the ability of the mutant viruses to replicate (figure 7).  Vero cells were infected on ice with the 
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indicated virus at an MOI of 5.  Virus was harvested 2, 4, 8, 12, 24, and 36 hours post-infection 
and titered on E5 cells.  The wildtype virus, KOS, grew most efficiently with a virus yield at 24 
hpi of 5.6 x 108 whereas the n12 did not grow above the levels of the initial inoculum and had a 
24 hour yield approximately 5 orders of magnitude lower than wildtype.  The d8-10 and d3-8 
viruses showed both delayed kinetics and a reduction in growth with the d8-10 virus reduced by 
about a factor of 10 at 24 hours and d3-8 slightly more impaired at 26 times less than wildtype.  
The loss of the C-terminus in the n208 virus resulted in delayed kinetics and severely impaired 
growth with only a slight increase in virus yield over that of inoculum at 24 hpi.  The mutant 
viruses nd8-10 and nd3-8 showed a dramatic reduction in growth similar to that of the 
nonfunctional n12, failing to reach the titer levels of the inoculum.  The nd3-8 mutant was more 
impaired, however compared to nd8-10.  The 3-8 deletion consistently shows a slightly greater 
reduction in viral growth than the 8-10 deletion, either in the context of full-length or lacking the 
C-terminus, suggesting the 3-8 mutation plays a more important role in viral growth.  The 8-10 
mutants are also impaired for growth, however, indicating that the entire N-terminal regulatory 
domain is needed for viral replication. In addition, mutants that lack both intact N- and C-
terminal regulatory domains are the most impaired for growth, suggesting the presence of one of 
the domains can somewhat compensate for the loss of the other. 
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Figure 7:  Effect of ICP4 mutations on viral growth. 
Vero cells were infected at an MOI of 5 with either the TAP virus or kos.  Virus was harvested 2, 4, 8, 12, 24, and 
36 hours pi.  Viral titers were determined via plaque assay on E5 cells. 
 
3.4.2 Functional analysis of mutant ICP4 
In order to first study the effects the mutations had on ICP4’s ability to regulate gene expression, 
the protein expression profiles of the mutant viruses were examined.  Vero cells were infected at 
an MOI of 10 with the indicated virus either in the presence or absence of PAA.  The cells were 
treated with 35S-methionine from 5-6 or 11-12 hpi to label newly synthesized peptides.  Whole 
cell lysates were prepared and separated via SDS-PAGE and labeled protein was visualized via 
autoradiography.  Three general protein expression profiles were seen based on wildtype KOS, 
the nonfunctional mutant n12, and the C-terminal truncation, n208.  At 6 hpi in the absence of 
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PAA, KOS expresses representative proteins from all classes of genes (figure 8, lane 16).  In the 
presence of PAA, however, KOS expresses increased levels of the early genes ICP6 and ICP8, 
reduced levels of the leaky late genes ICP5 and ICP25 and no true late genes due to the lack of 
DNA replication (figure 8, lane 8).   At 12hpi, KOS expresses low levels of E proteins and an 
abundant amount of both the leaky late (ICP25, ICP5, and gB) and true late proteins (ICP1/2, 
ICP19, ICP20, and ICP48, figure 8, lane 24).  Because n12 expresses a non-functional nonsense 
mutation of ICP4, it only expresses abundant IE without expressing early or late proteins.  Thus, 
its expression profile is the same at either 6 or 12 hpi in the presence or absence of PAA.  
Significant levels of ICP0, ICP27, and ICP6, an early protein that is responsive to ICP0 and is 
expressed in the absence of ICP4 (47, 50, 242), can be seen, however (figure 8, compare lanes 2, 
10, and 18).  The n208 virus shows significant changes in its protein expression profile.  The 
virus does not replicate its DNA to significant levels and thus does not express true late genes. 
As a consequence, E proteins accumulate at 6 hpi (figure 8, lanes 7 and 15).   By 12 hpi, some 
leaky late, but not true late, proteins can be seen (figure 8, lane 23).  
The deletion and truncation mutants all fit into the three general profiles (KOS-like, n12-
like, and n208-like) with some small differences.  Despite a reduction in replication efficiency, 
the d8-10 virus exhibited a KOS-like profile in all conditions with only a few exceptions.  In the 
presence of PAA at 6 hpi, d8-10 did express gB and ICP25, but to lower levels compared to 
wildtype (figure 8, compare lanes 4 and 8).  At 6 hpi in the absence of PAA, d8-10 expressed 
similar levels of the representative E proteins ICP6 and ICP8 as well as leaky-late proteins ICP5 
and ICP25.  It expressed similar levels of some true late proteins (L) as wildtype while 
expressing lower levels of the true late protein ICP19 and ICP20 and not expressing the true late 
proteins ICP1/2 and ICP48 (figure 8, compare lanes 12 and 16).  By 12 hours, however, 
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expression of the leaky-late and true late proteins began approaching the levels of KOS while 
ICP6 expression of d8-10 was significantly increased compared to wildtype (figure 8, lanes 20 
and 24) and was more similar to n12 (figure 8, lanes 20 and 18).  Thus, the 8-10 deletion results 
in a partial delayed-expression phenotype with some additional, gene-specific defects in 
regulation. 
Figure 8:  Protein expression profile of cells infected with the ICP4 deletion and nonsense mutants. 
Vero cells were infected with wildtype or mutant ICP4 viruses at an MOI of 10.  Either 6 or 12 hours post-infection 
(as indicated), the cells were treated with 35S-methionine for one hour to radiolabel newly translated proteins.  Total 
protein from cells infected with the indicated virus was harvested and resolved via SDS-PAGE.  The ICP 
designations of several viral proteins are shown. 
 
Members of the n208-like class include the nd8-10 and d3-8 viruses.  At 12 hpi, nd8-10 
accumulates lower levels of the leaky-late proteins ICP5 and ICP25 compared to n208 (figure 8, 
lanes 19 and 23).  In contrast to the KOS-like d8-10, d3-8 shows a very similar phenotype to 
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n208 at all times and conditions studied (figure 8, lanes 6 and 7, 14 and 15, 22 and 23).  Only the 
nd3-8 virus belongs to the n12-like class of protein profiles.  nd3-8 seems to be slightly more 
deficient in IE protein expression than n12, however, showing a reduced level of ICP27 and the 
ICP0-activated ICP6.  This study investigated the regulatory function of the mutant ICP4 
indirectly through protein levels.  Although changes in transcription rates do generally correlate 
directly with changes in protein levels, many other factors are involved in determining protein 
levels in the cell. 
In order to more directly assess the transcriptional efficiency of the mutant ICP4, relative 
mRNA abundance of prototypic IE gene (for repression) and E and L genes (activation) was 
assessed via northern blot analysis.  5 million vero cells were infected in the presence or absence 
of PAA at an MOI of 10 with the indicated virus.  6 or 12 hpi, the cells were harvested and total 
RNA isolated and quantified.  20 ng of mRNA from each sample was loaded onto a 
formaldehyde-agarose gel and separated over-night.  The mRNA was blotted onto a membrane 
and hybridized to probes specific for ICP4 (IE gene), tk (E gene), or gC (true late). Because the 
mRNA being probed for is identical in the case of tk and gC and only minimally changed in the 
case of ICP4, the mRNA processing and stability elements will be largely the same, thus making 
the rate of transcription the determining factor driving changes in message abundance.  
Comparing relative mRNA abundance between ICP4 mutants will provide insight into the effect 
of the mutations on regulatory function. 
The ICP4 promoter contains a strong ICP4-binding site near the transcriptional initiation 
site and thus is strongly repressed by functional ICP4 (48, 71, 143, 191, 198, 232).  As a result, 
KOS exhibits strong repression as shown by a low level of ICP4 mRNA in both PAA treated and 
untreated samples whereas the nonfunctional n12 exhibits an over-abundance of ICP4 mRNA 
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(figure 9A, top row, compare n12 and KOS).  Because the truncation mutants are a result of an 
insertion of a stop codon into the coding sequence and not a deletion, the size of the respective 
mutant mRNAs are not significantly changed nor is their mobility on a gel.  The ICP4 deletion 
mutants were constructed by actual deletion of the coding sequence, however, and as a result, run 
at a slightly higher mobility relative to wildtype and the truncation only mutants.  Compared to 
the non-functional n12, none of the other mutations had a significant effect on ICP4’s ability to 
repress its own transcription (figure 9A).  In both the PAA treated and untreated samples, the d3-
8 and n208 mutants show a slight increase in total ICP4 mRNA relative to wildtype (figure 9A, 
compare d3-8, n208, and KOS); however, these viruses clearly retain potent repressive function 
when compared to n12 (figure 9A, compare n12, d3-8, n208). 
Thymidine kinase was chosen as a prototypic E gene to analyze ICP4-mediated 
transactivation of E genes.  At 6 hpi, KOS accumulated an abundant amount of tk mRNA in both 
PAA treated and untreated samples (figure 9A), but by 12 hpi, less tk mRNA was present (figure 
9B) indicative of the switch from E to L gene expression.  In contrast, n12 accumulates 
undetectable or near undetectable levels in all times and conditions tested.  The n208 virus, 
which lacks the C-terminal transactivation domain, retained partial transactivation, at 6 hpi 
accumulating slightly lower levels of tk compared to KOS but significantly higher than n12 
(figure 9A, tk row).  By 12 hours, however, n208 exhibited similar levels of tk as KOS (figure 
9B, tk row).  The d8-10 mutant accumulated similar amounts of tk mRNA compared to KOS at 6 
hpi with a slight decrease in relative level in the PAA treated samples.  This is in contrast to the 
d3-8 mutant, which showed a significant reduction, but not complete loss, of tk accumulation 
(figure 9A).  The d3-8 level was comparable to the n208 mutant, which lacks the C–terminal 
transcriptional regulatory domain.  At 12 hpi, the d8-10 virus showed an increased level of tk 
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mRNA compared to wildtype, possibly a result of the partial-delayed kinetics shown in the 
growth curve and protein expression profile for this virus.  The d3-8 virus accumulated similar 
levels of tk message as both n208 and KOS (figure 9B).  At 6 hpi, the nd8-10 mutant in the PAA 
(-) sample accumulated lower levels of tk mRNA compared to n208 and a significant reduction 
compared to KOS.  This reduction was somewhat abrogated by PAA treatment. The nd3-8 
mutant, however, was comparable to n12, exhibiting nearly undetectable levels of tk in both 
PAA treated and untreated samples (figure 9A).  By 12 hpi, nd8-10 accumulated lower levels of 
tk than either n208 or KOS but higher levels than n12.  nd3-8 again expressed levels similar to 
n12 (figure 9B).   
 
Figure 9:  Accumulation of ICP4, tk, and gC transcripts in cells infected with deletion and nonsense mutants. 
A) Vero cells either in the presence or absence of PAA, as shown, were infected at an MOI of 10 with the indicated 
virus.  Total RNA was harvested 6 (A) or 12 (B) hours post-infection and relative ICP4, tk, and gC mRNA 
abundance was determined via northern blot analysis.  ICP4 normally represses the ICP4 gene and transactivates the 
tk and gC genes.  Efficient late gene transactivation requires the C-terminus of ICP4, thus all of the truncation 
mutants exhibit reduced gC expression. 
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The expression of gC, a prototypic true late gene, is somewhat complicated by its 
dependence on viral DNA replication and thus early gene expression.  An inability to express gC 
could be a result of either an indirect reduction in early gene expression or an inability to express 
gC directly.  At 6 hpi, KOS accumulates abundant gC mRNA whereas no signal is detected for 
n12.  The n208 virus exhibits a nearly undetectable level of gC message, despite robust early 
gene expression (figure 9A).  This virus, however, does not efficiently replicate its DNA (50).  
By 12 hpi, gC message remains abundant in KOS infected cells, while n12 and n208 show 
undetectable levels (figure 9B).  At 6 hpi, d8-10 exhibited similar levels of gC as KOS, while d3-
8 accumulated a significantly reduced, yet still detectable, amount (figure 9A).  This trend 
continued at 12 hpi with d8-10 comparable to KOS and d3-8 exhibiting an intermediate 
phenotype: reduced compared to KOS, but increased compared to n12 and n208 (figure 9B).  
The combination deletion and truncation mutants, nd8-10 and nd3-8, were strongly impaired in 
gC accumulation at both 6 and 12 hpi as they share the same truncation as n208 (figures 9A and 
B).  However, at 6 hpi, nd3-8 exhibited undetectable levels of gC mRNA whereas n208 and nd8-
10 both accumulated significantly reduced, yet still detectable, levels (figure 9A).  In summary, 
the 8-10 deletion mutants retain significant transactivation function.  The transactivation seen 
may be in part a result of the C-terminal transactivation domain compensating for the loss of the 
8-10 region, considering the nd8-10 mutant exhibits less accumulation of tk mRNA compared to 
n208.  This is in contrast to the 3-8 deletion; mutants lacking this region exhibit significantly 
reduced accumulation of both tk and gC mRNA.  The nd3-8 mutant, which lacks the c-terminal 
transactivation domain in addition to the 3-8 region, accumulates undetectable, or nearly 
undetectable levels, of the tk and gC transcripts. 
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3.4.3 Deletion mutants do not affect ICP4 DNA-binding 
ICP4’s ability to bind DNA has been shown to be necessary for its ability to regulate 
transcription (50, 208, 256).  In order to ensure functional changes seen in the mutants are a 
direct result of reduced regulatory function and not deficiencies in DNA-binding, electromobility 
shift assays were performed.  Vero cells were infected at an MOI of 10 with the indicated virus.  
Six hpi, cells were harvested and solubilized using 2% NP-40 to generate a whole-cell extract.  
This extract was incubated with a ?32P-ATP end-labeled probe consisting of the -108 to +27 of 
the ICP4 promoter, spanning the TATA box, transcription initiation site, and the ICP4 binding 
site.  The bound probe was separated on a native 4% PAGE gel and visualized via 
autoradiography. The mock-infected cell extract had several gel-shifted bands indicative of 
cellular proteins binding to the ICP4 promoter (figure 10, M).  All of the mutants studied, except 
n12 which expresses an ICP4 truncation that lacks the DNA-binding domain, retained the ability 
to bind DNA as shown by the gel-shifted band that is not found in the mock lane (figure 10).  In 
addition, these bands correlate with the relative size of the deletion/truncation mutants of ICP4, 
indicating the shifted band is due specifically to ICP4 binding to the probe.  The n208 truncation 
mutation increases the solubility of ICP4; thus, the mutants that contain this truncation, n208, 
nd8-10, and nd3-8, all bind more probe compared to their non-truncated counterparts, KOS, d8-
10, and d3-8, respectively.  The mutant that bound the least amount of probe, d8-10, retained 
near wildtype regulatory function (figures 8 and 9); thus, all the mutants studied (excluding n12) 
retained sufficient DNA-binding efficiency to preserve full regulatory function.  Any deficiency 
in transactivation or repression would therefore be due not to reduced DNA-binding but to a 
direct inability to regulate gene expression. 
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Figure 10:  DNA binding efficiency of the deletion and nonsense mutants. 
Vero cells were infected at an MOI of 10 either with KOS or an ICP4 mutant virus as indicated.  Total protein was 
harvested 6 hours post-infection in the presence of TLCK.  The extracts were incubated with a radiolabeled ICP4 
promoter probe and a nonspecific competitor for 30 min at room temperature and loaded onto a native 
polyacrylamide gel.  The first lane consists of the radiolabeled probe with no protein extract.  The rest of the lanes 
were incubated with extracts from cells infected with the indicated virus. 
 
ICP4 has been shown to form a tripartite complex with TBP and TFIIB on promoters that 
contain consensus ICP4 DNA-binding sites (266).  While the formation of TPCs has been 
associated with repression of transcription (11), it has also been shown that ICP4 interacts with 
TBP through TFIID in order to transactivate (26, 92).  It is unclear whether ICP4 makes multiple 
different contacts with the GTFs from within different regions of the peptide in order to activate 
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and repress or whether the same interacting domain is involved in both functions.  Because 
mutants containing the 3-8 mutation were significantly impaired in transactivation while 
retaining high levels of repression, they were tested for the ability to form TPCs.  Purified ICP4 
and TFIIB were incubated either in the presence or absence of recombinant TBP with the ?32P-
ATP end-labeled probe described above.  The binding reactions were then resolved via native gel 
electrophoresis on a 4% acrylamide gel at 200 volts.  Three distinct protein:DNA complexes 
were seen: TBP:TFIIB complex (DB) binding,ICP4 binding alone, and the TPC of ICP4:DB.  
The highest mobility complex, DB, was formed in all reactions TBP and TFIIB were co-
incubated (figure 11, *).  ICP4-binding could be seen both when incubated with TFIIB either in 
the presence or absence of TBP (figure 11, **).  The relative sizes of the mutant ICP4 molecules 
are reflected in the mobility of the ICP4:DNA complex.  The d3-8 ICP4 complex is not present 
in the TBP (-) reaction but is present in the TBP treated sample.  The 3-8 deletion does not, 
however, significantly effect DNA-binding, because a clear ICP4:DNA complex is seen in the 
TBP (-) sample, in the nd3-8 samples, and in the d3-8 whole cell extract sample (figure 10).  The 
largest complex is representative of the TPC and consists of ICP4, TBP, and TFIIB binding to 
the probe.  Both nd3-8 and d3-8 as well as n208 and KOS efficiently form the TPC on DNA 
(figure 11, ***).  As previously shown, the formation of the TPC is cooperative as seen by the 
marked increase in complex occupancy on the probe compared to both ICP4 and the DB 
complex alone.  In the KOS sample, additional, larger complexes are seen that are a result of 
ICP4 oligomerizing on the probe, a function of the C-terminus of ICP4 (146).  Thus, all of the 
mutants studied, except the nonfunctional n12, retain the ability to bind DNA.  This is expected 
as none of the mutations were made in the DNA-binding region of the protein.  In addition, the 
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3-8 deletion mutants retain the ability to form TPCs despite showing a reduced transactivation 
potential. 
 
 
Figure 11:  Tripartite formation on the ICP4 promoter by ICP4 mutants, TBP, and TFIIB. 
5 ng of purified wt or mutant ICP4 was incubated for 30 min at room temperature with TFIIB and radiolabeled ICP4 
promoter either in the presence or absence of TBP.  The complexes were separated on a native polyacrylamide gel 
and visualized via autoradiography. 
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3.5 DISCUSSION 
ICP4 is a critical regulator of viral gene expression.  Its function is affected in part via 
interactions with the cellular general transcription machinery that are mediated through two 
regulatory domains, a C-terminal and an N-Terminal domain (49, 50, 207, 256).  In this study, 
engineered viruses that express deletion and truncation mutants of ICP4 were used to dissect the 
contribution of different regions within the N-Terminal domain to the function of ICP4, either in 
the presence or absence of the C-terminal domain.  As summarized in figure 12, we show that 
while the entire N-terminal regulatory region is necessary for efficient function, in the context of 
infection, the 3-8 mutation exhibited a slightly more deleterious effect on ICP4 activity than the 
8-10 region.  Consistently through viral growth curves, protein expression profiles, and mRNA 
abundance of specific viral genes, the 3-8 deletion mutants showed a greater reduction in 
transactivation relative to both the 8-10 deletion and to wildtype.  No effect was seen in either 
deletion on the repressive ability of ICP4.  The mutant phenotype was not due to a reduced 
DNA-binding ability, however, as all of the mutants bound DNA in EMSA studies.  In addition, 
the 3-8 deletion mutants retained the ability to form TPCs on DNA with TBP and TFIIB, 
underscoring their role in repression, not transactivation. 
ICP4 shares extensive sequence similarity with other human alphaherpesviruses, 
including VZV.  These conserved regions correspond to regions of functional importance, 
including DNA-binding, nuclear localization, and transcription regulation.  The region with the 
most extensive similarity is the C-terminal domain.  The conserved region in the N-terminal 
regulatory domain is restricted to the polyserine tract, found in the 8-10 deletion.  A sequence 
alignment comparing HSV-1,  -2, and the herpes B virus however, revealed a second region of 
conversation, albeit limited to the most closely related herpesvirues to HSV-1 (figure 13).  This 
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region, found in the 3-8 region in between amino acids 81-91, is most likely responsible for the 
function attributed to the 3-8 region.  The fact that these regions are conserved amongst differing 
groups of viruses suggests they play distinct roles in ICP4’s function, an observation borne out 
by this study. 
 
Figure 12:  Summary of relative activities of mutant ICP4 used in this study. 
A) The primary sequence of ICP4 is shown with the various functional domains indicated by white boxes.  B) The 
peptides expressed by the mutants in this study are shown.  Their relative DNA-binding, transactivation, and 
repression function are indicated. 
 
 
 
Figure 13:  Regions of similarity between HSV-1, HSV-2, and herpes B virus ICP4 homologs in the N-
terminal regulatory domain.  
A sequence alignment was performed using the first 240 amino acids of HSV-1 ICP4, comparing the primary 
sequence of ICP4 in HSV-1, HSV-2, and the herpes B virus. 
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 Due to ICP4’s essential role in the viral life cycle, any impairment of viral function will 
have a direct effect on viral growth.  Truncation of ICP4 at amino acid 774, which yields a 
peptide lacking the C-terminal transactivation domain but is capable of both repression and 
activation of some viral genes (49, 50), significantly impaired, but did not abolish viral growth.  
This is in contrast to the truncation at aa 251, which yields a non-functional peptide that contains 
the N-terminal regulatory domain, but lacks DNA-binding (49, 50), and resulted in a complete 
loss of viral replication, underscoring ICP4’s dependence on DNA-binding for its function.  
Deletion of parts of the N-terminal regulatory domain with the DNA-binding and C-terminal 
domains intact resulted in a less severe reduction in viral growth as compared to n208.  The d3-8 
deletion virus showed a slightly larger reduction in growth as the d8-10 virus, however both 
regions, aa 30-142 and 143-210, are required for normal viral growth.   The growth of n208, d3-
8, and d8-10 indicate that although required for wildtype growth, neither the intact N- or C-
terminal regulatory domains are necessary to maintain some low level of viral replication.  
Viruses that lack both intact transcriptional domains, however, do not grow.  Interestingly, loss 
of the C-terminus alone results in a slightly greater than two orders of magnitude reduction in 
growth (n208 compared to KOS) while loss of only either the 3-8 or 8-10 region results in a 
reduction of 1 to 1.5 orders of magnitude, respectively, when compared with KOS.  This 
suggests the C-terminus plays a larger role in viral growth, despite the observation that mutants 
lacking C-terminus retain both repressive and transactivation function.  Deletion of both the 
entire N-terminal regulatory domain and the c-terminus after aa 774, however, yields a dominant 
negative mutant (257) making it difficult to study the contribution of the C-terminus in the 
absence of the entire N-terminal regulatory domain.  Comparison of n208 to KOS, d3-8 to nd3-8, 
and d8-10 to nd8-10 allows the assessment of cooperativity between the N- and C-terminal 
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regions.  Loss of the C-terminus with an intact N-terminal region results in a slightly larger than 
2 orders of magnitude reduction in growth (figure 7, compare n208 to KOS) whereas the loss of 
the c-terminus while lacking either aa 30-142 or aa143-210 results in a drop of approximately 3 
orders of magnitude (figure7, compare nd3-8 to d3-8, nd8-10 to d8-10).  The loss of either the 3-
8 or 8-10 region has the same impact in viral growth (1-1.5 orders of magnitude reduction) 
independent of the c-terminus (figure 7, compare KOS to d3-8 and d8-10, n208 to nd3-8 and 
nd8-10).  This suggests that the C-terminal regulatory domain is uniquely sensitive to the lack of 
intact N-terminal domain whereas the N-terminal domain’s function is less dependent on the C-
terminus; the N-terminus may, therefore, play a role in the function of the C-terminus. 
In addition to growth curve studies, global viral replication was assessed via protein 
expression profiles.  In general, the deletion mutant viruses fit into three categories relative to the 
protein profiles of the control viruses: KOS-like, n208-like (exhibiting a slight reduction in Early 
genes, a significant impairment of leaky late genes, and no expression of late genes, and n12-
like, no expression of early or late genes.  Interestingly, the deletion mutants did not group with 
their control counterparts.  While d8-10 did belong to the KOS-like group, d3-8’s protein profile 
was more similar to n208’s; nd8-10 behaved more like n208, but nd3-8 had more similarities to 
the nonfunctional n12.  In addition, the protein expression profiles did not always correlate with 
the growth curves.  While the d8-10 and d3-8 mutants have relatively similar growth kinetics 
(figure 7), their protein expression profiles are significantly dissimilar (figure 8), suggesting a 
different etiology for their similar replicative phenotypes. 
The relative mRNA abundance of the tk and gC transcripts underscore the importance of 
the different transcriptional regulatory domains.  The inability of C-terminal truncation mutants 
to accumulate gC mRNA agree with previously published data showing the importance of the C-
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terminus to activate late genes (figure 9) (49, 50).  The mRNA abundance data for the N-terminal 
deletion mutants agree with the growth curve and protein expression data showing the 
importance of both aa 30-141 and 142-210 to be necessary for normal transactivation (figure 9).  
Interestingly, our data showing the importance of the 3-8 region in ICP4-mediated 
transactivation is in direct contrast with previously published results showing the 8-10 region is 
required while the loss of the 3-8 region has no effect on transactivation (256). The previous 
work, however, was done using transient transfection of plasmids expressing the ICP4 deletion 
and a CAT reporter plasmid under the control of the tk promoter, whereas the studies shown here 
are in the context of viral infection and directly measuring tk mRNA abundance.  The 8-10 
region clearly plays an important role in ICP4-mediated transcription that is less relevant in the 
context of infection than in transfection, and conversely, the 3-8 region plays a critical role in 
transactivation in the context of infection but not transfection.  Transfected plasmids are rapidly 
integrated into nucleosomal structures in mammalian cells (90, 225).  These structures are 
largely repressive in nature, and this repression can be counter-acted by the viral promiscuous 
transactivator ICP0 at least partially through its disregulation of cellular HDACs (96, 163).  In 
the absence of IE gene expression, viral genomes rapidly associate into a repressive nucleosomal 
state. The virus acts to counteract this both directly on IE promoters through VP16-mediated 
HAT activity and globally through ICP0’s disregulation of cellular HDACs (96, 114, 163).  In 
addition, HSV infection rapidly and dramatically alters the host cell, creating an environment 
that favors viral over cellular gene expression.  ICP0 induces a general, pro-transcription state in 
the cell(67, 84, 197); ICP22 triggers an aberrantly phosphorylated form of RNA pol II (76, 77, 
229); and HSV infection induces the phosphorylation of Sp1 (139), the loss of TFIIA expression 
(312), and the marginalization of the cellular DNA. The 8-10 region of ICP4 may be important 
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for ICP4 transactivation from a more closed, repressed chromatin state formed in the absence of 
viral factors while the 3-8 region may be be necessary for transactivation from a more open 
template and a transcription environment heared more for viral gene expression.  The 8-10 
region may therefore play a role in reactivation from latency when the viral genome is in a 
repressive chromatin state (53). The polyserine tract, which is located in the 8-10 region, has 
indeed been shown to be involved in viral growth and reactivation in neurons.  Viral mutants that 
are lacking the polyserine tract replicate in the corneas of mice, albeit at a reduced level; 
efficiently infect the TG; but exhibit a dramatic reduction in growth and reactivation in neurons 
(12). 
ICP4’s DNA-binding is necessary but not sufficient for its regulatory function (50, 208, 
256).  All of the mutants in this study, except the non-functional n12, retain ICP4’s DNA-
binding domain.  EMSA studies verify that these mutants all retain the ability to bind DNA, 
making any change in regulation a result of altered function and not DNA-binding.  Interestingly, 
the role DNA-binding takes in ICP4’s function differs between repression and activation.  
Despite no clear DNA-binding site, ICP4 acts, in a DNA-binding dependent manner, to recruit 
and stabilize pre-initiation complexes on promoters for transactivation (26, 92).  In repression, 
ICP4 forms a TPC on the DNA through binding of a strong ICP4-binding site and interactions 
with TBP and TFIIB (94, 145, 266).  The position of the ICP4 binding site relative to the TATA 
box directly correlates with strength of repression (145, 157).  The ability of the transactivation 
defective but repression competent nd3-8 and d3-8 mutants to form TPCs in vitro (figure 11) 
underscores the role the TPC plays in repression, specifically.  The role DNA-binding plays in 
ICP4’s function is becoming increasingly more complex, however.  ICP4 has been shown to 
oligomerize on DNA through its C-terminus, thus creating a relative high-affinity for the DNA 
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through an additive effect of multiple molecules binding at a lower affinity (146).  ICP4’s 
stabilization of PICs on viral promoters may also act to reciprocally stabilize ICP4 on the DNA.  
Indeed, ChIP analysis has shown the cooperative recruitment of TBP and ICP4 on L genes in a 
C-terminus and Inr dependent fashion, most likely through interactions with TAF1.  The C-
terminus truncated mutant n208 does not oligomerize on DNA, does not directly interact with 
TAF1, expresses some, but not all, early genes, inefficiently replicates its DNA, and does not 
express late genes. In repression, the already high affinity of ICP4 for its binding site is increased 
through the cooperative formation of the TPC (266).  Thus, ICP4’s DNA-binding is critical for 
regulation, functionally variable, and carefully modulated both through DNA sequence 
specificity and through stabilization of low-affinity binding through protein-protein interactions.  
Coarse, in vitro DNA-binding assays such as EMSA and DNAse footprinting may therefore not 
be sufficient to fully delineate between the subtle variations in DNA-binding in vivo that 
determine ICP4 transcriptional regulation.  
ICP4 is a large, complex molecule with several domains that contribute to its function as 
a critical regulator of viral transcription.  Extensive effort has been made to map the regions of 
the protein that affect its function.  Studies of truncations of ICP4 have shown that the N-
terminal 774 amino acids are sufficient for ICP4-meditated repression and transactivation (49, 
50).  This truncation mutant, while retaining transactivation function, showed a reduced 
expression of some early and leaky late genes, a severe impairment in DNA-replication, and no 
late gene expression indicating the importance of the C-terminus for some transactivation 
function.  Interestingly, small, temperature sensitive mutations made in the C-terminus can result 
in a loss of ICP4 function at the non-permissive temperature that is retained by mutants lacking 
the C-terminus, suggesting a role in protein folding and stability (37, 46, 55, 209, 219).  This 
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complexity coupled with the inability to isolate discreet regulatory domains in the N-terminus 
suggest ICP4’s true regulatory domains are a result not of simple linear primary sequences as is 
common in most transcription factors, but a complex tertiary structure that may act as a platform 
to mediate multiple protein-protein contacts.  The targeted mutagenesis of the discreet stretches 
of similariy between the closely related HSV-1, -2, and herpes B virus, and the polyserine tract 
that is conserved amongst the alphaherpesviruses will provide further insight into these 
functional domains and how they functionally and perhaps physically interact with each other 
and the C-terminus.  The dependency of the C-terminus on an intact N-terminal regulatory 
domain presented here and the role the C-terminus plays in ICP4 protein folding raises the 
possibility of an intramolecular interaction between the N- and C-terminal regulatory domains.  
The GTF TFIIB contains a highly conserved charged cluster domain in the N-terminus that 
mediates a functionally relevant intramolecular interaction with the c-terminus, resulting in a 
dynamic equilibrium of open and closed confirmation TFIIB (109, 110, 233).  In addition, the 
successive phosphorylation of Rb by a variety of cdks induces sequential, intramolecular 
interactions that incrementally regulate the function of Rb, including its dissociation with 
HDACs (104).  Similarly, the phosphorylation of the polyserine tract in the N-terminal 
regulatory domain of ICP4 seen during infection (302, 303) may provide an effective way to 
dynamically alter the intramolecular interaction between the N- and C-terminus, thus modulating 
the structure of ICP4’s tertiary activation domain and subsequently, its activity.  This complexity 
would reflect the need to regulate transcription from multiple, divergent promoters through 
dynamic changes in the cellular transcriptional milieu induced as the viral life-cycle progresses. 
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4.0  PROTEINS INTERACTING WITH ICP4 DURING HSV-1 INFECTION 
4.1 ABSTRACT 
The infected cell polypeptide 4 (ICP4) is a critical regulator of viral gene expression and is 
required for productive infection. Because viral genes are transcribed by the cellular RNA 
polymerase II (RNA pol II), ICP4 must interact with the host machinery to regulate viral gene 
expression. It has been shown previously that ICP4 interacts in vitro with several members of the 
general transcription factors (GTFs), including TATA box-binding protein (TBP), TFIIB, and the 
TBP-associated factor 1 (TAF1). These interactions correlate with ICP4’s ability to regulate 
transcription.  In this study, the cellular transcription machinery contacted by ICP4 during 
infection was further characterized using tandem affinity purification (TAP). A virus that 
expresses TAP-tagged ICP4 under the control of its native promoter in a wild- type KOS 
background was engineered. The resulting virus grew with similar kinetics as wildtype and 
expressed comparable levels of TAP-ICP4.  Nuclear extracts were prepared from isolated nuclei 
of infected HeLa cells via high salt extraction and submitted to TAP using IgG and calmodulin 
beads.  The purified material was separated via SDS-PAGE, stained with colloidal blue, and gel 
slices were prepared.  The gel slices were submitted to in-gel trypsin digestion, and the resulting 
peptides were eluted from the gel.  The peptides were then analyzed via ESI-LC/MS, which 
identified 46 peptides with high confidence.  One of the proteins identified was L22, a cellular 
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translation factor that was previously shown to interact with ICP4 via a two-hybrid screen.  
Proteins of particular interest found to copurify with ICP4 were TBP and several TAFs, TFII-I, 
and components of the Mediator complex.  The role of Mediator in ICP4-mediated 
transactivation was further investigated using immunofluorescence and chromatin 
immunoprecipitaion.  Mediator was found to colocalize with ICP4 starting at early and 
continuing into late times of infection.  In addition, Mediator was recruited to viral promoters in 
an ICP4-dependent manner.  Together, the data show that ICP4 interacts with components of the 
basal transcription machinery and coactivator complexes in the context of viral infection to 
regulate viral gene expression. 
4.2 INTRODUCTION 
During lytic infection, HSV-1 exhibits a strictly regulated temporal cascade of gene expression 
that is divided into three general stages, immediate early (IE) or ?, early (E) or ?, and late (L) or 
? (120, 121).  This expression program is a result of a complex interplay between viral and 
cellular factors at both the transcriptional and translational level that is poorly understood.   The 
IE protein ICP4 is a critical regulator of viral gene expression and is required for productive 
infection (48, 198, 217).  It activates E and L genes while repressing its own transcription, giving 
ICP4 a crucial role in establishing the gene expression cascade.  
ICP4 regulates gene expression through interactions between its two broad regulatory 
domains, DNA, and various cellular factors.  It exists as a large, 350 kDa homodimeric 
phosphoprotein in the cell and has N- and C-terminal transcriptional regulatory domains that are 
separated by a dimerization domain, nuclear localization sequence, and DNA-binding domain 
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(49, 50, 81, 207, 208, 256).  ICP4 binds DNA to a degenerate consensus seqeunce, 
ATCGTCNNNNYCGRC where R = purine, Y = pyrimidine, and N = any base (72, 78).  ICP4 
has also been shown to bind DNA nonspecifically.  DNA binding is required for ICP4-mediated 
transcriptional regulation, with specific binding sites associated with repression and non-specific 
binding important in transactivation (35, 61, 64, 102, 265).   
Because viral genes are transcribed by the cellular RNA polymerase II (RNA pol II), the 
virus must recruit the host machinery to regulate viral gene expression (8, 41). Cellular 
transcription is traditionally thought to be initiated through a step-wise assembly of the pre-
initation complex (PIC) consisting of the GTFs (TFIID, TFIIA, TFIIB, TFIIF, TFIIE, and TFIIH) 
and RNA pol II (21, 190, 202). The efficiency of formation of the PIC is a critical step in 
determining the rate of transcription and is thus a common site of both positive and negative 
transcriptional regulation (9, 31, 82, 159).  TFIID, a large protein complex consisting of the 
TATA binding protein (TBP) and its associated factors (TAFs), is important for promoter 
recognition and acts as a scaffold on which the rest of the PIC nucleates (21, 193).  ICP4 has 
been shown to stabilize the formation of PICs on viral promoters in vitro via enhancement of 
TFIID binding to the promoter through direct interactions in vitro with both TBP and TAF1 of 
the TFIID complex (26, 92). In addition, ICP4 cooperatively forms a stable, tripartite complex 
(TPC) on DNA with TBP and TFIIB at promoters containing the ICP4 binding site in vitro (145, 
266).  The formation of the TPC localizes to regions of ICP4 that are also required for efficient 
repression of activated transcription suggesting the TPC has a suppressive effect on promoters 
(94, 145).  Formation of the TPC specifically inhibits activated transcription at a step prior to 
elongation while allowing basal transcription to proceed.  This implies it does not simply 
preclude binding of the PIC to the promoter (95).  Thus, ICP4 interferes with the action of 
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upstream activators through formation of TPCs to negatively regulate transcription from these 
promoters.   
ICP4 mediates both positive and negative transcriptional regulation through complex 
interactions with DNA and several members of the cellular transcriptional machinery.  It is 
unclear, however, what prevents robust activation of late genes until the onset of DNA 
replication and the decline in E gene expression after DNA replication despite the continued 
presence of ICP4 at these promoters.  In this study, the cellular transcription machinery contacted 
by ICP4 is further characterized using tandem affinity purification (TAP).  TAP is a general 
purification scheme that purifies native protein complexes from the cell through use of a bipartite 
tag consisting of two IgG binding domains from Staphylococcus aureus protein A and a 
calmodulin binding peptide (CBP) separated by a tobacco etch virus (TEV) protease cleavage 
site (220, 230). A virus that expresses an N-terminally TAP-tagged ICP4 under the control of its 
native promoter in a wild-type KOS background was engineered.  Nuclear extracts were 
prepared from isolated nuclei of infected HeLa cells via the Dignam method (54) and submitted 
to TAP.  The previous studies investigating ICP4 protein interactions were done in vitro with 
uninfected cellular extracts that do not reflect the conditions found in infected cells.  HSV 
infection has been shown to significantly alter the host transcriptional environment (77, 139, 229, 
312).  Isolating ICP4 complexes in the context of infection allows for the characterization of 
protein interactions made in the natural protein stoichiometry that occurs during infection. 
SDS-PAGE analysis of TAP-purified samples shows a multipart mixture of proteins 
complexing with ICP4.  Mass spectrometry and western blot analysis identified several proteins 
that co-purify with ICP4, including TBP, several TAFs, TFII-I and subunits of the Mediator 
complex, among others.  Colocalization studies using immunofluorescence show Mediator 
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subunits are recruited to viral replication compartments at early times of infection and persist 
into late infection.  In addition, chromatin immunoprecipitation studies show the association of 
Mediator at promoters representative of all three major classes of genes, and this association is 
increased in the presence of ICP4, thus ICP4 recruits Mediator to viral promoters most likely to 
enhance their transcription.  These data show the intricacies of viral gene regulation and suggest 
ICP4 may play a broader role in transcriptional regulation, acting to stimulate the formation of 
PICs both through recruitment of TFIID as well as mediator and potentially other cellular factors 
to the promoter.  The dynamic nature of the cellular transcriptional environment during the 
course of infection, distinct promoter structures of each class, and a potential broader role for 
ICP4 in gene activation suggest the activation of the IE, E, and L gene classes may be through 
distinct mechanisms, thus allowing for the strictly regulated cascade of expression exhibited 
during lytic infection. 
4.3 MATERIALS AND METHODS 
4.3.1 Cells and viruses 
HeLa, vero, HEL, and E5 cell lines were all maintained by standard procedures.  E5 cells were 
derived from vero cells and express complementing levels of ICP4 (47, 49).  The HeLa, Vero, 
and HEL cell lines were all obtained from ATCC.  Both the HSV-1 wildtype strain KOS and 
TAP-ICP4 viruses were propagated on Vero cells while the nonfunctional ICP4 nonsense mutant 
n12 (50) was grown on E5 cells. Viral growth curves were performed on vero cells.  5 x 105 cells 
were infected on ice with KOS or TAP-4 HSV-1 at an MOI of 5.  Virus was allowed to adsorb 
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for 1 hour on ice, then cells were washed twice with cold Tris-buffered saline (TBS) containing 
0.25 mM Tricine, 137 mM NaCl, 5 mM KCl, 0.5 mM MgCl2, and 0.68 mM CaCl2, pH 7.35.  
The infection was allowed to proceed at 37oC for 2, 4, 8, 12, 24, or 36 hours as indicated.  Cells 
were then scraped into the media, freeze-thawed twice, and sonicated.  Viral titers were 
determined on E5 cells via plaque assay. 
4.3.2 Construction of the TAP-ICP4 virus 
A virus expressing an N-terminally TAP-tagged ICP4 was constructed.  The plasmid pcDNA 
Zome-N containing the N-terminal TAP tag construct was digested with EcoRI.  The 
overhanging ends were filled in using Klenow enzyme (NEB) and ligated together with T4 DNA 
ligase (NEB).  The resulting plasmid was then digested with HindIII, the overhanging ends were 
filled in, and a SalI linker (NEB) was ligated to the blunt ends.  The construct was then digested 
with PstI and SalI to free the tag construct from the plasmid.  The TAP-construct was then 
inserted into the ICP4-containing pi2 plasmid (256) digested with PstI and SalI to form the 
NTAP-pi2 plasmid.  The NTAP-pi2 plasmid was then used to rescue the ICP4 nonsense mutant 
n12, as described previously (12).  Plaque isolates were screened by Southern blot, and 
successful recombinants were submitted to several rounds of plaque purification.  The resulting 
TAP-ICP4 virus expresses ICP4 from its native promoter with the TAP tag replacing the first 17 
amino acids of ICP4. 
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4.3.3 TAP procedure 
The TAP protocol was performed as described previously with several modifications 
(220).  1.5 x 109 HeLa cells were infected with either KOS or TAP virus in DMEM 5% FBS at 
an MOI of 10.  The infection was allowed to proceed for six hours at 37oC, after which the cells 
were scraped into the media and pelleted via centrifugation at 5000 RPM for 5 minutes at 4oC.  
All remaining steps were done at 4oC.  The cells were washed twice in a total volume of 40 ml 
TBS plus 0.2mM PMSF, 0.2mM N?-p-tosyl-L-lysine chloromethyl ketone (TLCK), and 0.5mM 
DTT added just prior to use.  The cells were then pelleted at 2000 RPM for five minutes, and 
nuclear pellets were then prepared following the Dignam method with some modifications (54).  
The cell pellet was first resuspended in hypotonic buffer (10 mM Hepes pH 7.9, 1.5 mM MgCl2, 
10 mM KCl) containing 0.2 mM PMSF, 0.2 mM TLCK, and 0.5 mM DTT using approximately 
five times the pellet volume.  The cells were pelleted at 2000 RPM for five minutes and then 
then resuspended again in hyptonic buffer containing 0.2 mM PMSF, 0.2 mM TLCK, and 0.5 
mM DTT (approximately three times initial pellet volume) and incubated for ten minutes on ice.  
The cell suspension was then transferred to a pre-chilled small wheaton dounce homogenizer to 
disrupt the cellular membranes (about 15 strokes).  The efficiency of douncing was assessed via 
staining with trypan blue.  The nuclei were the pelleted by centrifugation at 3000 rpm for 10 
minutes.  The nuclei were gently resuspended in half the total pellet volume using low salt buffer 
(20 mM Hepes pH 7.9, 25% glycerol, 1.5 mM MgCl2, 20 mM KCl, 0.2 mM 
ethylenediaminetetraacetic acid (EDTA)) containing 0.2 mM PMSF, 0.2 mM TLCK, and 0.5 
mM DTT added just prior to use.  High salt buffer (20 mM Hepes pH 7.9, 25% glycerol, 1.5 mM 
MgCl2, 1.6 M KCl, 0.2 mM EDTA) with 0.2 mM PMSF, 0.2 mM TLCK, and 0.5 mM DTT 
using one third total volume of nuclear suspension was then added to the suspension dropwise 
 79 
for a final KCl concentration of 400 mM.  Samples were incubated for 30 minutes at 4oC with 
gentle mixing.  The extract was then clarified via centrifugation at 14,500 rpm for 30 minutes at 
4oC.  250 μl (~125 μl packed volume) IgG-Sepharose 6 Fast Flow bead suspension (Amersham 
Biosciences) was added to four Poly-prep chromatography columns (BioRad).  The beads were 
equilibrated by washing in five ml equilibration buffer (50 mM Tris-HCl pH 7.6, 150 mM NaCl, 
and 0.05% Tween-20) followed by 5 ml 0.5 M acetic acid, pH 3.4, 5 ml equilibration buffer, and 
10 ml IgG binding buffer (15 mM Hepes pH 7.9, 1.5 mM MgCl2, 200 mM KCL, 0.1% NP40, 
and 0.5 mM EDTA) with 0.2 mM PMSF, 0.2 mM TLCK, and 0.5 mM DTT.  The nuclear 
extracts were diluted approximately two-fold in IgG binding buffer with 0.2 mM PMSF, 0.2 mM 
TLCK, and 0.5 mM DTT and added in equal amounts to the four columns.  Extracts were 
incubated at 4oC for four hours with gentle end-over-end rotation.  Unbound extract was allowed 
to drain from the column.  The column was then washed with 5 ml of IgG binding buffer with 
0.2 mM PMSF, 0.2 mM TLCK, and 0.5 mM DTT, 5 ml without PMSF or TLCK but with 0.5 
mM DTT, and 5 ml TEV protease buffer (10 mM Tris pH 8.0, 150 mM NaCl, 0.1% NP40, 0.5 
mM EDTA) containing 1 mM DTT added just prior to use.  The columns were then incubated 
overnight at 4oC in 1 ml TEV protease buffer containing 10 μl (100 U) AcTEV protease 
(Invitrogen) and 10 μl (250 U) Benzonase nuclease (Novagen) per column to release the bound 
proteins from the column and to digest any contaminating DNA in the sample.  The eluates from 
the columns were drained into a new tube.  Three ml calmodulin binding buffer (10 mM Tris-
HCl pH 8.0, 10 mM ?-mercaptoethanol, 150 mM NaCl 1 mM MgAcetate, 1 mM imidazole, 2 
mM CaCl2, and 0.1% NP-40) with an additional 3 μl 1 M CaCl2 (1 μl/ml) to ensure saturation of 
residual EDTA was passed through the column and combined with the eluate from above for 
efficient collection of eluted protein complexes for a total of approximately 16 ml eluate in 
 80 
calmodulin binding buffer.  500 μl (~250 μl packed volume) calmodulin affinity resin 
(Stratagene) was added to two poly prep columns and equilibrated 3x with 5 ml calmodulin 
binding buffer.  8 ml of eluate was then added to each calmodulin column and incubated with 
rotation for 4 hours at 4oC.  The columns were then washed in 10 ml calmodulin wash buffer (10 
mM Tris-HCl pH 8.0, 10 mM ?-mercaptoethanol, 150 mM NaCl 1 mM MgAcetate, 1 mM 
imidazole, and 2 mM CaCl2).   The bound complexes were then eluted in 10 ml calmodulin 
elution buffer (10 mM Tris-HCl pH 8.0, 10 mM ?-mercaptoethanol, 150 mM NaCl 1 mM 
MgAcetate, 1 mM imidazole, and 2 mM ethylene glycol tetraacetic acid (EGTA)), combined, 
and concentrated using iCON concentrators, 7ml/9k (Pierce). 
4.3.4 Mass spectrometry 
Purified TAP samples were separated via SDS-PAGE and visualized using a colloidal blue 
staining kit (Invitrogen) following manufacturers protocol.  Gel slices were excised for the length 
of the gel and submitted to in-gel trypsin digestion as described previously (258).  The resulting 
peptide mixture was separated by capillary C18 HPLC using a ThermoElectron Surveyor liquid 
chromatograph, and the effluent was directly analyzed on a ThermoElectron LCQ Deca XP Plus 
quadrupolar ion trap mass spectrometer using a nanospray ionization source.  The instrument 
collected both MS and MS/MS spectra.  The data was analyzed and searched against both human 
and HSV-1 Uniprot/Swissprot databases using the SEQUEST search engine in the BioWorks 
Browser, version 3.3.1 SP1 (Thermo Fisher Scientific, Inc.).  The MS analysis was performed by 
the Genomics and Proteomics Core Laboratories at the University of Pittsburgh. 
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4.3.5 Western blot analysis 
TAP-purified samples were separated via SDS-PAGE and analyzed via western blot as 
previously described (255).  The antibodies used were diluted in 50 mM Tris, pH 7.5, 150 mM 
NaCl, and 0.05% Tween-20 (TBS-T) and 1% milk.  They were as follows: 1:5000 dil of N15, a 
rabbit polyclonal specific to the N-terminus of ICP4 as previously characterized (255); 1:500 
TBP (233R, Covance); 1:100 TAF1 (Santa Cruz); 1:100 TAF4 (Santa cruz, sc-736), 1:2500 
TAF4 (152); 1:1000 ICP0 1112 (Rumbaugh-Goodwin Institute); 1:1000 ICP27 1113 
(Rumbaugh-Goodwin Institute); 1:250 CRSP77 (Santa cruz); 1:100 Med7 (Santa cruz); and 
1:1000 TRAP220 (Santa cruz).  The secondary antibodies used were 1:5000 dilutions of an anti-
rabbit, anti-mouse, and anti-goat polyclonal IgG-HRP conjugates (Promega) in TBS-T.  Bound 
antibody was visualized using the ECL Plus Western Blotting Detection System (Amersham) per 
manufacturer’s protocol. 
4.3.6 Immunofluorescence 
One day prior to infection, HEL cells were plated onto coverslips.  1 x 106 HEL cells were plated 
in 60 mm dishes with four round coverslips per dish.  The next day, the cells were infected with 
KOS at an MOI of 10 on ice.  The cells were chilled on ice and treated with ice-cold inoculum in 
TBS.  The virus was allowed to adhere for one hour on ice with periodic gentle rocking after 
which the inoculum was removed and replaced with warm media.  The infections were allowed 
to proceed for two, four, and eights hours.  Subsequently, the media was removed, and the cells 
were washed once in warm phosphate buffered saline (PBS).  The cells were fixed with 1% 
paraformaldehyde (PFA) in PBS for 11 min at 37oC.   The PFA was removed, and the cells were 
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incubated at room temperature in PBS containing 100 mM glycine to stop the reaction.  The cells 
were washed for five minutes in room temperature PBS three times and then incubated in 50 mM 
NH4Cl in PBS for 10 minutes.  The cells were permeabilized with 0.5% triton X-100 in PBS 
with 1% bovine serum albumen (BSA) for 15 minutes and then washed in PBS-T (PBS with 
0.1% triton X-100) and 1% BSA three times for 10 minutes each.  The primary antibodies were 
diluted in PBS-T and 1% BSA.  The antibodies used were: 1:500 dilution of N15 (rabbit 
polyclonal) for ICP4 and 1:1000 dilution for TRAP220 (Goat polyclonal, Santa cruz).  The cells 
were incubated for two hours with 100 ?l antibody dilution per slide.  The coverslips were 
washed with PBS-T containing 15 BSA six times 10 minutes each.  The appropriate secondary 
antibodies (donkey anti-goat Alexa Fluor488 or donkey anti-rabbit Alexa Fluor595 both from 
Invitrogen) were diluted 1:500 in 100 ?l per coverslip PBS-T and 1% BSA and incubated on the 
slides for one hour in the dark.  The coverslips were washed in PBS-T eight times seven minutes 
each in the dark.  The coverslips were then mounted on glass slides using Immu-mount (Thermo 
Scientific).  The slides were analyzed and images captured using a Leica DMI4000 B 
microscope. 
4.3.7 Chromatin immunoprecipitation 
ChIP assays were performed as described previously with some exceptions (247).  One day prior 
to infection, 5 x 106 vero cells were plated onto 100 mm dishes.  The following day, the cells 
were infected on ice in cold TBS at an MOI of 10 with the indicated viruses.  The virus was 
allowed to adsorb for one hour on ice with gentle, periodic rocking, after which the inoculum 
was removed and replaced with warm media.  The infections were allowed to proceed for four 
hours prior to formaldehyde fixation.  Sonicated chromatin was harvested as described 
 83 
previously (247).  The samples were pre-cleared using protein A and G agarose beads with 
salmon sperm DNA (Millipore 16) as described.  The primary antibodies (3 ?l purified n15 for 
ICP4, 1 ?l 8WG16 (Covance) for RNA pol II, and 1.5 ?l each of TRAP220 (Santa Cruz) and 
CRSP77 (Santa cruz) for Mediator were pre-treated and bound to the appropriate protein A and 
G beads for four hours at 4oC with gentle mixing.  Unbound antibody was washed away using 1 
ml ChIP dilution buffer 3 times 5 minutes each.   Pre-cleared sample was then incubated with the 
antibody:bead mixture overnight at 4oC with gentle mixing.  The bound protein complexes were 
washed, eluted, uncross-linked, and digested using proteinase K as described previously (247).  
The released DNA was harvested via phenol:chloroform extraction followed by ethanol 
precipitation and resuspended in 150 ?l H2O.  The DNA was then analyzed via RT-PCR using 
SYBR GreenER qPCR SuperMix (Invitrogen) as described previously (247).  The primers used 
for the PCR reaction are shown in table 1.  
 
Table 1:  Primers used for PCR 
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4.4 RESULTS 
Transcription of viral genes follows a strictly regulated temporal cascade and is mediated 
through the cellular general transcription factors and RNA pol II.  Several lines of evidence have 
shown that  the cellular machinery is altered during the course of infection, resulting in a 
changing pool of available factors, which may contribute to the implementation of the cascade.  
ICP4, however, is required for the proper activation of both E and L gene classes.  ICP4 has been 
shown to interact in vitro with both TBP and TAF1 of TFIID, and these interactions are required 
for ICP4 to function in reconstituted transcription reactions (26, 145, 266).  In addition, the C-
terminus of ICP4 is required for activation of L but not E genes (49, 50).  The evidence that 
transcription of the classes of viral genes is mediated through distinct cellular complexes and 
different regions of ICP4 suggests ICP4 activates transcription through the recruitment of 
different cellular complexes to distinct promoter classes.   In this study, we used tandem affinity 
purification (TAP) to determine the protein interactions made by ICP4 during infection.  We also 
investigated the relevance of a subset of these interactions in vivo through immunofluorescence 
and chromatin immunoprecipitation studies. 
4.4.1 Characterization of TAP-ICP4 
Tandem affinity purification (TAP) was used to investigate the protein interactions made by 
ICP4 during infection.  TAP uses dual purification steps to gently and specifically purify large 
complexes while reducing contaminating false-positives.  The TAP-tag, consisting of two IgG 
binding domains from Staphylococcus aureus protein A and a calmodulin binding peptide (CBP) 
separated by a tobacco etch virus (TEV) protease cleavage site (220, 230), was inserted into the 
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N-terminal ICP4 coding region and then recombined into the viral locus via homologous 
recombination as described in the materials and methods.  The tag was added to the N-terminus 
because it has previously been shown to tolerate addition of other epitopes (26).  Successful 
recombinants were plaque purified and confirmed via Southern blot.  The TAP-tag was inserted 
at amino acid 17 of ICP4, resulting in the loss of the first 17 amino acids and is under control of 
the native ICP4 promoter (figure 14A).  Proper protein expression and size were confirmed via 
western blot.  Vero cells were infected with the non-functional nonsense mutant n12, TAP-ICP4, 
or wildtype KOS.  Whole cell lysates were prepared 6 hours post-infection and submitted to 
western blotting, probing with n15, a polyclonal antibody to the N-terminal 774 amino acids of 
ICP4.  Wildtype ICP4 has an apparent molecular weight of 175 kDa; whereas, TAP-ICP4 
exhibits a slightly lower mobility when compared to wildtype, corresponding to the additional 
184 amino acids (approximately 21 kDa) of the TAP-tag (figure 14B).  The mutant n12 
expresses a severely truncated protein of approximately 41 kDa.  Both wildtype and TAP-ICP4 
were expressed to similar levels showing the addition of the tag did not disrupt ICP4 regulation 
or protein stability.  The n12 mutant has dramatically lower levels of the truncated ICP4.  This is 
most likely due to inefficient recognition of the truncated protein by the n15 antibody as the n12 
mRNA is greatly overexpressed due to loss of ICP4’s repressive function (see Chapter 3). 
Viral growth curves were performed to assess the effects of the addition of the tag on 
viral growth.  Because ICP4 is required for replication, any effect on ICP4 function will result in 
altered viral growth. Vero cells were infected on ice with either KOS or TAP-ICP4 at an MOI of 
5.  Virus was harvested 2, 4, 8, 12, 24, and 36 hours post-infection and titered on E5 cells.  Both 
the KOS and TAP-ICP4 viruses exhibited similar growth, showing the addition of the TAP-tag 
does not significantly impact viral replication or ICP4 function (figure 14C). 
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Figure 14:  Generation and characterization of TAP-ICP4. 
A) Schematic comparing the primary sequence of the ICP4 peptides expressed by the viruses used in this study.  The 
TAP-tag is shown in red.  B) Expression of the ICP4 peptides from cells infected with the indicated virus was 
assessed via western blot of whole cell extracts from vero cells infected with the indicated virus.  The proteins were 
visualized with the ICP4-specific antibody n15.  C) The effect of the addition of the TAP-tag on viral growth was 
analyzed via growth curve.  Vero cells were infected at an MOI of 5 with either the TAP virus or KOS.  Virus was 
harvested 2, 4, 8, 12, 24, and 36 hours pi.  Viral titers were determined via plaque assay. 
 
4.4.2 Optimization of TAP purification of ICP4 
The TAP method purifies protein complexes using two affinity steps, an irreversible prot A:IgG 
interaction and the reversible CBP:calmodulin interaction.  This allows for a gentle, but specific 
isolation of complexes from cells.  The preparation of the protein extracts prior to purification is 
a critical step in any purification scheme.  It is crucial to efficiently isolate the target protein 
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while retaining the integrity of any complexes to which it participates.  We chose to prepare 
protein extracts using the Dignam high salt extraction method; a method that is commonly used 
to prepare transcriptionally active nuclear extracts (54).  Both the nuclear extraction and TAP 
procedure were optimized for maximal ICP4 purification.  Nuclei were isolated from TAP-ICP4 
infected HeLa cells 6 hours post-infection as described in the materials and methods.  The 
isolated nuclei were divided into 4 treatments and extracted in buffer containing 150, 200, 300, 
or 500 mM KCl.  The resulting nuclear extracts were submitted to the TAP procedure.  Both 
unconcentrated  (-) or concentrated (+) TAP-purified samples were separated via SDS-PAGE 
and visualized by silver staining (figure 15A).  ICP4, the dark band near the top of the gel, was 
most efficiently isolated using 200 and 300 mM KCl.  There was a marked reduction in ICP4 at 
500 mM KCl, due, at least in part, to the lysing of the nuclei resulting in significant DNA 
contamination and reduction in the extract yield.  Despite only a slight difference in total ICP4 
isolated at 200 and 300 mM KCl, there is an increase in proteins copurifying with ICP4 at higher 
salt, as shown by the increased banding complexity at 300 mM KCl.  Indeed, the 500 mM KCl 
sample had less ICP4 than the 200 mM salt, but had more copurifying proteins.  Thus ICP4 
extraction exhibits a slight salt dependence, but the proteins with which it interacts have a greater 
dependence, with the most efficient copurification at higher salt concentrations. 
The experiment outlined above measured the final, TAP-purified samples. It is possible 
that any change in protein complex purification could be attributed to the efficiency by which the 
individual proteins are initially extracted from the nucleus.    To test this, the concentrated TAP-
purified samples from above along with aliquots from the corresponding nuclear extracts were 
separated via SDS-PAGE and submitted to western blotting (figure 15B).  The blots were probed 
with antibodies for ICP4 and TBP (figure 15B, upper left and lower left, respectively).  TBP was 
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chosen because it has been shown to interact with ICP4 in several studies.  There was a slight 
increase in the amount of ICP4 purified at higher KCl concentrations, as seen by silver staining.  
There was a corresponding slight increase in total ICP4 initially extracted from the nucleus, 
suggesting the efficiency of TAP-ICP4-pull down is primarily dependent on the initial nuclear 
extraction (figure 15B, upper left).  In contrast, extraction of the 37 kDa TBP was not affected by 
the salt concentration used, but, in accordance with the pattern seen in the silver stained gel, it 
only copurified with ICP4 at higher KCl concentrations (figure 15B, lower left).  The high 
molecular weight bands seen in the nuclear extracts of the TBP blot correspond to the Prot A 
domain of the TAP-tag binding to the antibody used in the western blot.  This band is not seen in 
the final, purified lanes because the Prot A domain is cleaved from the tag as part of the 
purification procedure.    This shows that the TAP procedure is capable of successfully isolating 
ICP4-containing protein complexes, and that at least a subset of these complexes is only 
efficiently extracted from the nucleus at high salt concentrations. 
In order to confirm the salt dependency of complex extraction and purification, nuclei 
were again isolated but were extracted with only the 300 mM or 500 mM KCl buffers.  The 
nuclear extracts were purified via TAP, and the concentrated TAP-purified samples and their 
corresponding nuclear extracts were submitted to western blotting.  The resulting blots were 
probed with TBP and TAF1 (figure 15B, lower right and upper right, respectively), both of 
which have been shown to interact with ICP4.  Again, there was no difference in the amount of 
either TBP or TAF1 in the 300 and 500 mM KCl nuclear extracts.  There was a slight increase in 
the total amount of TBP that copurified with ICP4 in the 500 mM KCl sample.  TAF1, however, 
showed a dramatic increase in copurification from the 300 to 500 mM KCl extracted samples.  
Thus, ICP4 protein complexes containing TBP and TAF1 are tightly retained in the nucleus and 
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require high salt to efficiently extract them, whereas TBP and TAF1 not interacting with ICP4 do 
not require high salt.  In addition, at least a portion of ICP4:TBP complexes appear to not include 
TAF1, as shown by the TBP copurifying with ICP4 at 300 mM salt compared to the relative little 
amount of TAF1 interacting.  These experiments indicate that the highest KCl concentration that 
could reliably be employed to prepare the nuclear extracts should be used.  Unfortunately, the 
500 mM KCl buffer often resulted in nuclear lysis during purification; as a result, 400 mM KCl 
was used in all subsequent TAP experiments. 
 
 
 
Figure 15:  Effect of KCl concentration on protein extraction and complex isolation via TAP. 
A) Isolated nuclei from infected HeLa cells were divided into 4 samples and submitted to TAP using increasing KCl 
concentrations of 150, 200, 300, and 500 mM for protein extraction. The resulting TAP-purified samples were 
separated via SDS-PAGE before and after concentration and protein bands visualized via silver staining.  B) Nuclear 
extracts and concentrated TAP samples from A were probed for ICP4 and TBP via western blot.  The high 
molecular weight band in the nuclear extract is the protein A subunit of the TAP-tag binding to the secondary 
antibody during western blotting.  This band is absent in the TAP purified lane due to the cleavage of the protein A 
domain during purification. C) The experiment in A was repeated with the 300 and 500 mM KCl concentrations and 
probed via western blot for TBP and TAF1. 
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4.4.3 Characterization of proteins copurifying with ICP4 
The goal of this study was to characterize those proteins with which ICP4 forms complexes 
during the course of infection.  TAP was used to isolate those complexes and mass spectrometry 
was used to characterize them.  1.5 x 109 HeLa cells were infected with either KOS or TAP-
ICP4.  Six hours post-infection, the cells were harvested and ICP4 protein complexes were 
isolated using the TAP procedure as described in the materials and methods.  The purified 
protein complexes were separated via SDS-PAGE and visualized via silver and colloidal blue 
staining (figure 16).  Many more proteins were isolated by TAP from the TAP-ICP4 compared to 
KOS infected nuclear extracts; however, some proteins were purified from the KOS nuclear 
extracts, suggesting a low frequency of non-TAG specific purification.   As expected, ICP4 was 
the major component of the purified samples (figure 16, TAP-ICP4 major 175 kDa band) due to 
both its being the target protein for purification and its higher abundance compared to most 
cellular proteins. 
 
Figure 16:  Visualization of total proteins interacting with ICP4. 
TAP-purified samples from nuclear extracts of TAP-ICP4 and KOS infected cells were prepared.  Samples were 
separated via SDS-PAGE, and total protein was visualized by A) silver stain and B) colloidal blue stain in 
preparation for MS analysis. 
 91 
 In preparation for the mass spectroscopic analysis, the purified samples were separated 
via SDS-PAGE and visualized with colloidal blue (figure 16).  To ensure characterization of 
both high- and low- abundance constituents, gel slices were excised from the length of the TAP-
ICP4 lane with an emphasis on clearly visible bands.  The proteins were digested in situ with 
trypsin and the resulting peptides were eluted from the gel and characterized via LC-MS/MS.   
The analysis identified with high confidence 46 proteins listed in table 2.  The Uniprot, protein 
name, probability score (Ppro) assigned by the SEQUEST software, and molecular weight of the 
protein are indicated.  The Ppro score is the probability that the protein listed is a random match 
to the spectral data.  Only those proteins with a Ppro score of less than 10-3 are listed.  The 
proteins were initially categorized on whether they were identified from gel slices of the 
appropriate molecular weight.   Of the 46, 14 were identified from gel slices corresponding to 
incorrect weights.  This does put the identity of these proteins in question; however, the inherent 
inefficiency in protein separation using SDS-PAGE and the possibility of degradation products 
in the gel may explain this discrepancy. 
The remaining 32 proteins were further divided into four categories:  viral proteins, 
transcription factors, calmodulin binding proteins, and other, miscellaneous proteins.  Two 
proteins that have previously been shown to interact with ICP4, TBP and L22, were identified.  
The L22 and ICP4 interaction was shown through a two-hybrid screen (158).  The isolation of 
L22 via TAP and the identification via MS shows again that TAP and MS are valid methods of 
isolating and characterizing ICP4 protein complexes, respectively.  Of particular interest for this 
study are the 11 transcription factors found to copurify with ICP4.  TFIID has previously been 
shown to interact with ICP4, and the identification of TBP and 8 TAFs verifies the in vitro 
findings.  Interestingly, TAF1 was not identified in the MS analysis, despite being present as 
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shown by western blot (figure 15).  Whether this is due to inefficient separation vis SDS-page, 
inefficient trypsin digestion, inefficient elution from the gel, or general recalcitrance to MS 
identification is unclear.  In addition to components of TFIID, MS analysis also identified Med8, 
a component of the Mediator complex, and TFII-I, a transcription factor important for Inr-driven 
transcription were all identified to copurify with ICP4. 
Several proteins found in the TAP-purified samples are likely not interacting with ICP4 
but are present as a result of the purification system used.  IgG kappa chain C is most likely a 
contaminant from the IgG column, and 7 proteins have previously been shown to interact with 
calmodulin (108, 268, 280, 282, 285).  These contaminating false positives are most likely 
responsible for the proteins found in the KOS-infected lane in the silver stained gel (figure 16).  
Indeed, the strong, approximately 50 kDa band found in both the TAP-ICP4 and KOS infected 
lanes corresponds to the calmodulin-binding elongation factor 1-?1 and 2. 
The MS analysis identified only two viral proteins: ICP4 and, interesting, the US3 kinase.  
ICP4 has previously been shown to interact in vitro with both ICP0 and ICP27 (204, 309) but 
neither was identified in the MS analysis.  To confirm the MS results, western blot analysis was 
performed on TAP-purified samples from both KOS and TAP-ICP4 infected cells.  Samples 
were harvested as submitted to western blotting using antibodies against ICP4, ICP0, and ICP27 
as described previously.  Significant amounts of ICP4, ICP0, and ICP27 were all detected in the 
nuclear extracts lane derived from TAP-ICP4 infected cells (figure 17).   Significant levels of 
ICP4 were detected in the TAP-ICP4 purified lane, but none were detected from the KOS lane, 
thus ICP4 purification via TAP is dependent on the presence of the TAP-tag.  No ICP0 or ICP27 
was detected in either the KOS or TAP-ICP4 purified lanes showing in these conditions, ICP4 
does not interact with ICP0 or ICP27. 
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Table 2:  Proteins identified by MS analysis. 
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Figure 17:  Interaction of ICP4 with ICP0 and ICP27. 
TAP-purified samples from nuclear extracts of TAP-ICP4 and KOS infected cells were prepared.  Samples were 
separated via SDS-PAGE and submitting to western blotting using antibodies against ICP4, ICP0, and ICP27. 
 
4.4.4 ICP4 interaction with TFIID 
As mentioned previously, ICP4 has been shown to interact with both TBP and TAF1, 
both components of TFIID, through a variety of in vitro methods, and through these interactions, 
stimulate PIC formation and transactivation (26, 92).  It has been extrapolated from these data 
that ICP4 interacts with TFIID, a large cellular complex made up of 14 subunits.  TBP and 
several other TAF components of TFIID were identified in ICP4-containing complexes isolated 
via TAP (table 2).  In order to confirm those results and to ensure their association is specific to 
the TAP-tagged ICP4, western blot analysis was performed on purified samples from KOS and 
TAP-ICP4 nuclear extracts as described above.   The resulting blots were probed for specific 
subunits of TFIID: TAF1, TAF4, TAF7, and TBP (figure 18), two of which (TAF4 and TBP) 
were identified via MS.  All four proteins were detected both in the TAP-ICP4 nuclear extract 
and the TAP-ICP4 lane.  None were detected in the KOS infected lane, showing that isolation via 
TAP required TAP-ICP4.  Thus, ICP4 interacts with several subunits of TFIID, including TBP, 
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TAF1, -3, -4, -4b, -5, -6, -7,-9b, -10, and -13 as shown either by MS or western blot of TAP-
ICP4 complexes.   
 
 
Figure 18:  Interaction between ICP4 and TFIID. 
TAP-purified samples from nuclear extracts of TAP-ICP4 and KOS-infected cells were prepared.  Samples were 
separated via SDS-PAGE and submitted to western blotting using antibodies against TAF1, TAF4, TAF7, and TBP. 
 
 
 
4.4.5 ICP4 interacts with Mediator and recruits it to viral promoters. 
The Mediator component Med8 was identified via MS in ICP4-complexes purified via TAP.  
Mediator is a large cellular protein complex made up of over 30 subunits.  It functions primarily 
as a bridge between upstream activators and the GTFs and RNA pol II.  Western blot analysis 
was used to confirm the presence of Mediator subunits in TAP-purified ICP4 complexes, as 
described previously.  Western blots were probed for three distinct subunits of Mediator: 
TRAP220, CRSP77, and Med7 (figure 19A).  Antibodies to Med8, the subunit identified in the 
mass spectroscopic analysis, were unavailable.  TRAP220, CRSP77, and Med7 were all detected 
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specifically in the TAP-ICP4 lane, showing again that their copurification required the presence 
of TAP-tagged ICP4.   
 
Figure 19:  Interaction and colocalization of ICP4 and Mediator. 
A) TAP-purified samples from KOS and TAP-ICP4 infected cells were prepared.  Samples were separated via SDS-
PAGE and western blotted for TRAP220, CRSP77, and Med7. B) HEL cells were infected at an MOI of 10.  The 
infections were allowed to proceed for 2, 4, or 8 hpi pror to fixation and treatment for immunfluorescence.  The cells 
were stained for ICP4 (red) and TRAP220 (green).  An enlarged view of a representative cell from the merged panel 
is also shown. 
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VP16, the viral transactivator integral to IE gene activation, has previously been shown to 
interact with Mediator subunits (306).  Mediator has not, however, been implicated in ICP4-
mediated expression of either E or L genes.  In order to investigate the kinetics of ICP4-Mediator 
association, immunofluorescence of infected HEL cells was used.  HEL cells were infected at an 
MOI of 10 with KOS and fixed at 2, 4, or 8 hours post-infection (figure 19B).  The cells were 
then stained with antibodies directed against the Mediator component TRAP220 in green and 
ICP4 in red.  A digitally magnified view of a single, representative HEL cell as shown by the 
white box is also shown.  As expected, no ICP4 signal was seen in the Mock infected cells.  By 2 
hpi, a subset of infected cells are expressing ICP4 as seen by a diffuse, nuclear stain with several 
small ICP4 foci.  At least a subset of these foci contain viral genomes and are sites of viral 
transcription and, later, DNA replication (269).  By 4 hpi, ICP4 can be seen localizing into small 
replication compartments, which by 8 hpi, are fully matured.  TRAP220 exhibits a diffuse, 
primarily nuclear staining.  HSV infection, however, induces a dramatic reorganization of 
TRAP220.  As early as 2 hpi, those cells expressing ICP4 show recruitment of TRAP220 into the 
small, ICP4-containing foci.  As infection proceeds and the ICP4 foci enlarge and mature, 
TRAP220 recruitment to and colocalization with ICP4 continues.  Thus, TRAP220, and by 
extension Mediator, is recruited to ICP4 foci early in infection and continues through late times 
of infection. 
The previous experiments suggest Mediator plays a direct role in ICP4-mediated viral 
transcription.   In order to test this, Mediator recruitment by ICP4 to promoters representative of 
the three classes of viral genes was assessed via chromatin immunoprecipitation.  Vero cells 
were infected at an MOI of 10 with n12 or KOS, and ChIP analysis was performed 4 hpi as 
described in the materials and methods.  The association of ICP4, RNA pol II, and Mediator to 
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the ICP0, tk, and gC promoters was analyzed as a function of wildtype (KOS) or nonfunctional 
(n12) ICP4.  The data is represented as the total number of genomes precipitated determined by 
qRT-PCR as described previously (figure 20). The primers used to amplify the ICP0, tk, or gC 
promoters are described in table 1.  As expected, wildtype ICP4 was found at high levels at all of 
the promoters tested; whereas the n12 ICP4, which lacks a DNA-binding domain, was not 
detected (figure 20, left panel).  Thus, comparison of protein association to promoters in KOS 
and n12 infected cells allows for analysis of the role functional ICP4 plays in recruitment of 
these proteins. 
 
Figure 20:  Binding of ICP4, RNA pol II, and Mediator to the ICP0, tk, and gC promoters in KOS and n12 
infected cells. 
ChIP analysis was peformed 4 hpi to assess the binding of Mediator and RNA pol II to the ICP0, tk, and gC 
promoters as a function of ICP4 and DNA replication.  The total genomes bound and the percent genomes relative to 
the input are shown. 
 
 
IE genes reach peak expression between two and four hours, after which their expression 
declines.  Thus, at four hours, there should be robust expression of ICP0, an IE gene 
representative.  In addition, gene expression profiles of KOS and n12 show that n12 
overexpresses IE genes compared to KOS showing that IE gene expression is independent of 
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ICP4 function.  Indeed, previous ChIP studies have shown RNA pol II is efficiently recruited to 
ICP0 promoters independently of ICP4 (247).  As expected, the data in figure 20 show that RNA 
pol II associates with the ICP0 promoter both in the presence (KOS) and absence (n12) of 
functional ICP4 (figure 20, middle panel).  By analogy, Mediator recruitment should also be 
independent of ICP4.  Interestingly, there was a higher association of Mediator at ICP0 
promoters in KOS compared to n12 infected cells (figure 20, right panel).  This may be 
explained in part by an increase in total viral genomes due to low levels of viral DNA replication 
at 4 hpi seen in  KOS but not n12, which does not replicate its DNA.  It may also be due to a 
more efficient recruitment of Mediator by ICP4 compared to VP16 or an artifact of the 
experimental system. It is possible that the transcription complexes assembled by VP16 on ICP0 
may partially block the antibody binding sites on TRAP220 and CRSP77 used for the assay, thus 
reducing the efficiency of antibody pulldown. 
E gene expression reach maximal levels between 4 and 6 hour post-infection and are 
dependent on functional ICP4.  As expected, RNA pol II is associated to the tk promoter 4 hpi in 
an ICP4 dependent manner, with over 10 fold less associated during n12 infection compared to 
KOS (figure 20, middle panel).  Similarly, Mediator recruitment to the tk promoter also required 
functional ICP4 with a similar, over 10-fold increase in Mediator association during KOS 
infection compared to n12.   
Late gene expression reaches peak levels after E genes and the onset of DNA replication 
and requires functional ICP4 for expression.  Thus, at 4 hpi, robust Late gene expression would 
not be expected.  Previous ChIP studies have shown, however, that TBP and RNA pol II 
associate to gC in the absence of DNA replication and Late gene expression in an ICP4 
dependent manner.  Indeed, RNA pol II associates maximally with the gC promoter only in the 
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presence of ICP4 (figure 20, middle panel).  Likewise, efficient Mediator association also 
required functional ICP4 with just under a 10-fold increase in KOS infected cells.  In summary, 
figure 20 shows that Mediator is found associated to promoters of representatives of all three 
classes of viral genes.  In addition, the association of Mediator was increased in the presence of 
functional ICP4.  This, combined with the data showing Mediator is a component of purified 
ICP4 protein complexes, suggests that ICP4 recruits Mediator to promoters. 
4.5 DISCUSSION 
ICP4 is the major viral transcriptional regulator, and is necessary for the proper expression of all 
three major classes of viral genes (48, 198, 217).  It represses its own transcription and 
transactivates both E and L genes.  Several studies have shown that ICP4 interacts with both 
TBP and TAF1 of TFIID through N- and C-terminal regulatory domains to recruit and stabilize 
PICs on the promoter (26, 92).  These interactions are critical for it to regulate transcription.  
ICP4’s large size, complicated transcription regulatory domains, and ability to activate a diverse 
set of promoters, however, suggest ICP4 may play a broader role in stimulating transcription 
than recruitment of TFIID.  To investigate this possibility, ICP4 containing complexes were 
isolated from infected cells using TAP.  The proteins contained in these complexes were 
characterized by MS and western blot analysis.  The data show that in addition to TFIID, ICP4 
interacts with other cellular factors, including Mediator and TFII-I.  The role of Mediator in 
ICP4 transcription was further analysed using IF and ChIP assays, showing that Mediator 
associates at representative promoters of the three classes of viral genes.  Additionally, efficient 
Mediator recruitment required ICP4.  Taken together, the data show that ICP4 plays a broader 
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role in viral transcription than recruitment of TFIID to the promoter and provide further insight 
into the regulation of the viral gene expression cascade. 
4.5.1 Complex isolation and characteriztion 
The goal of this study is to isolate and characterize protein complexes formed by ICP4 during 
infection in vivo.  Because we were particularly interested in ICP4’s transcription regulation, the 
ICP4 complexes were extracted from the nucleus of infected cells prior to purification using the 
Dingham method of purifying transcriptionally active nuclear extracts (54).  The copurification 
of TBP and TAF1 with ICP4 confirm the previous in vitro data (26, 92).  In addition, the cellular 
ribosomal protein L22 was identified by the MS analysis.  L22 has previously been shown to 
interact with ICP4 via a two-hybrid screen (158).   The characterization of proteins previously 
shown to interact with ICP4 validate the TAP method as an efficient method of isolating ICP4 
protein complexes as well as the capacity of MS and western blot analysis to characterize them.  
The MS analysis was unable to identify all the proteins in the TAP-purified complexes, however, 
as shown by the western blot identification of several proteins, including TAF1, TAF7, 
TRAP220, Med7, and CRSP77, not identified by MS.  Whether this was due to insufficient 
amounts of these proteins in the sample or their general incompatibility with MS identification is 
unclear.  Thus, although the MS analysis identified several components of ICP4 complexes, it is 
not comprehensive. 
The MS analysis identified several novel proteins.  Many of these proteins can be 
discounted, however, due either to known interactions with calmodulin used during the 
purification procedure or due to purification from gel slices of inappropriate molecular weight.  
Those proteins that bind to calmodulin are isolated not based on interactions with ICP4 but with 
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interactions with the affinity resin used during purification.  As a result, they can be seen in 
samples prepared from TAP-ICP4 and KOS infected extracts (figure 16, table 2).  
In addition to the calmodulin-binding proteins, several identified proteins were found in 
gel slices corresponding to the incorrect molecular weight.  This does not necessarily mean the 
identification is false, however, as protein degradation and inefficient separation by SDS-PAGE 
could explain the discrepancy.  The identification of these proteins should be treated with some 
skepticism, however, and most of these proteins’ relationship with HSV infection is unclear.  
One notable exception is CoREST, which is part of a complex that is thought to be disrupted 
during HSV infection (96), and hence a potential interaction between it and ICP4 may warrant 
further investigation. 
4.5.2 ICP4 copurification with protein kinases 
The MS analysis also identified two kinases of interest, the HSV Us3 kinase and casein kinase II 
(CKII).  ICP4 is heavily phosphorylated during the course of infection, and the poly-serine tract, 
a major site of ICP4 phosphorylation, has consensus sites for the cellular kinases protein kinase 
A (PKA), PKC, and CKII.  ICP4 is phosphorylated in vitro by PKA and PKC (302, 303).  The 
serine tract and its phosphorylation by PKA are important for viral growth, particularly in 
neurons (12).  An interaction between CKII and ICP4 and the presence of CKII consensus sites 
on ICP4 suggest ICP4 may also be phosphorylated in vivo by CKII.  This analysis is 
complicated, however, by the observation that CKII also phosphorylates calmodulin (240).  
Thus, presence in the purified sample may be due to an interaction with calmodulin, not ICP4. 
In addition to CKII, the Us3 kinase was also found in the TAP-purified ICP4 complexes.  
The Us3 kinase has multiple roles during HSV infection, including the phosphorylation of 
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histone deacetylases 1 and 2, CoREST, and UL34, among other viral and cellular proteins (136, 
216, 222).  It plays an important role in preventing apoptosis in infected cells, promotes capsid 
egress from the nucleus, and may play a role an indirect role in the induction of the aberrantly 
phosphorylated form of RNA pol II during infection (15, 58, 189).  Although it has not been 
shown to directly phosphorylate ICP4, studies of the VZV homologs of Us3 (Orf66) and ICP4 
(IE62) have shown that Orf66 phosphorylates IE62 near its NLS to regulate its nuclear 
localization during infection (307).  ICP4 and IE62 do exhibit similar localization patterns during 
infection, being predominantly nuclear early in infection and then becoming cytoplasmic late in 
infection.  The change in IE62 localization is more dramatic than ICP4, however, making it 
unclear if there is a similar mechanism in regulating ICP4’s localization.   
4.5.3 ICP4 interaction with TFII-I 
The only transcriptionally related protein that copurified with ICP4 and does not take part in 
large protein complexes is TFII-I.  TFII-I is a cellular protein involved in both basal and 
activated transcription through its recognition of the Inr element of the core promoter (238).  It is 
required, along with TFIID, for activation of TATA- Inr+ but not TATA+ promoters (168).   In 
addition, TFII-I initiates the formation of PICs that are distinct from those formed by TFIIA, as 
shown by differential mobility in EMSA studies (237).  Taken together, this suggests that TFII-I 
may play a role specifically in L gene expression, as L gene promoters are the only viral 
promoters that contain an Inr (298), and L gene expression does not require TFIIA (312).  The 
Inr element is necessary for the L gene’s TFIIA independent expression. Thus, TFII-I fits very 
well with what is known of HSV biology.  The ICP4-TFII-I interaction was unable to be 
confirmed, however, by either western blot or IF (data not shown).  This does not necessarily 
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refute a potential ICP4:TFII-I interaction, as both western blot and IF analysis are dependent on 
proper antibody:antigen recognition, whereas MS is not.  ICP4 may interact with a form of TFII-
I that is not recognized by the monoclonal antibody used in these assays.  Further study needs to 
be performed to clarify the role TFII-I plays in ICP4 mediated transactivation of viral genes. 
4.5.4 TAF-containing complexes and ICP4 function 
Previous in vitro studies have shown that ICP4 regulates transcription at least in part through 
direct interactions with both TBP and TAF1 of TFIID (26, 92).  In addition, immunfluorescence 
studies have shown that components of TFIID, including TBP, TAF1, and TAF4 are reorganized 
during HSV infection and colocalize with ICP4 (223).  Finally, ChIP assays have shown that 
TBP recruitment to representative E and L promoters during infection is dependent on ICP4 
(247).  The copurification of both TBP and TAF1 with ICP4 shown here (figure 18, table 2) 
confirms the previous studies.  The additional identification of TAF3, -4, -4B, -5, -6, -7, -9B, -
10, -13 (figure 18, table 2) shows that ICP4 stably associates with the entire TFIID complex.  
Interestingly, an ICP4:TBP complex lacking TAF1 can also be isolated (figure 15).  This 
suggests ICP4 forms at least two distinct complexes with TBP: one with TAF1 and one without.  
It is reasonable to assume that the complex containing both TBP and TAF1 corresponds to 
TFIID.  The complex lacking TAF1, however, is less clear.  ICP4 has previously been shown to 
participate in a tripartite complex with TBP and TFIIB on an ICP4 DNA binding site that is 
associated with ICP4-mediated repression (94, 145, 266).   The ICP4:TBP complex lacking 
TAF1 may be reflective of this tripartite complex. 
In addition to TFIID, several other TAF-containing complexes have been described. 
These complexes, including TFTC, STAGA, and PCAF, all play a role in activator-dependent 
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transcription, adopt structures similar to that of TFIID, and share many of the same enzymatic 
activities, including HAT, and may play a role in recruiting TBP to promoters (192, 252).   It has 
recently been proposed that a subset of TAFs (TAF4, -5, -6, -9, and -12) form a stable a scaffold 
on which TFIID and the other TAF-containing complexes are formed (300).  Interestingly, 
TAF4, -5, -6, and -9, were all shown to copurify with ICP4 (figure 18, table 2).  TAF12 was also 
identified to copurify with ICP4 in a second MS experiment (data not shown).  Thus, all of the 
components of the TAF subcomplex copurify with ICP4.  It is possible that, in addition to 
TFIID, ICP4 may activate transcription through interactions with other TAF-containing 
complexes via this core TAF subcomplex. 
4.5.5 Role of Mediator in ICP4-mediated transactivation 
In addition to TFIID, components of the Mediator associate with ICP4 during infection (figure 
19, table 2).  Mediator is a large, multisubunit complex that acts as a general cofactor, bridging 
activators and the general transcription machinery, primarily through facilitating the entry of pol 
II into the PIC (129, 154, 276, 279).  It also plays a role in activator-dependent stabilization of 
the scaffold complex that enhances transcription reinitiation from the same promoter (311).  The 
complex can be divided into three domains, the head, middle and tail.  The head domain 
primarily interacts with pol II while the middle and tail domains interact with upstream 
activators, thus executing its bridging function (18, 27, 38). The mediator subunits identified in 
this study are found in different regions of the mediator complex; both Med8 and CRSP77 
localize to the head region of mediator while Med7 and TRAP220 are found in the middle 
region.  The copurification of components from two distinct regions of Mediator suggests ICP4 
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associates with the entire complex.  Although Mediator has been shown to interact with other 
viral activators, including HSV VP16, this is the first evidence for an interaction with ICP4. 
ICP4 is involved in the proper expression of all three phases of viral gene expression.  As 
this is the first evidence for an ICP4:Mediator interaction, it is unclear what role Mediator plays 
in ICP4-mediated transcription regulation.  The ICP4 complexes used for TAP that showed an 
ICP4-Mediator interaction were isolated at 6 hpi, at which there is both E and L gene expression.  
In order to try and determine the temporal role an ICP4:Mediator interaction may play during 
infection, immunofluorescence studies were performed.   
There was a significant reorganization of TRAP220 during infection, with strong co-
localization of ICP4 and TRAP220 starting at early and proceeding through late times of 
infection (figure 19).  The characterization of a VP16:Mediator interaction suggests Mediator is 
involved in IE gene expression (306).  The strong colocalization between ICP4 and Mediator 
suggests an additional role in E and L gene expression. 
The role Mediator plays in E and L gene expression was confirmed via ChIP assay.  
Figure 20 shows that Mediator is present at all three classes of genes, confirming the IF data, and 
that Mediator association is greatly increased in the presence of ICP4.    Because ICP4 is 
required for the expression of both E and L genes, it is possible that the Mediator recruitment to 
these promoters is due to their active transcription rather than recruitment by ICP4. Several lines 
of evidence suggest, however, that Mediator is recruited to the promoter by ICP4.  First, the 
copurification of Mediator with ICP4 suggests a direct interaction between them, as expected in 
the case of ICP4-mediated recruitment.  In addition, ICP0 expression is independent of ICP4, 
and is efficiently transcribed both in n12 and KOS infections.  Mediator association on the ICP0 
promoter was also increased in the presence of ICP4, suggesting Mediator recruitment is not 
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simply due to active transcription.  Finally, at 4hpi, late genes are not robustly expressed, thus 
recruitment of Mediator to these promoters is most likely not due simply to active transcription.  
As mentioned previously, this is the first evidence of an ICP4:Mediator interaction.  
IE62, the VZV homolog of ICP4, has recently been shown to interact with Mediator, however.  
The N-terminal acidic activation domain of IE62 was shown to directly interact with Med25 of 
Mediator and IE62 recruits Mediator to an IE62 responsive promoter (307).  Although IE62 and 
ICP4 share significant sequence similarity, ICP4 does not contain an acidic transcription 
activation domain.  IE62’s interaction with Mediator is more similar to VP16’s interaction with 
Mediator.  VP16 also interacts with Med25 through an acidic activation domain (306), 
suggesting a common Mediator-interaction motif.  ICP4, which lacks an acidic activation 
domain, must interact with Mediator through a different mechanism.  Thus, the interaction with 
Mediator appears to be conserved amongst the alpha-herpesvirus major transactivators, but 
appears to have arisen through distinct evolutionary pathways.  The implications of this are 
unclear but present an intriguing distinction between ICP4 and IE62 and their function. 
The goal of this study was to isolate and characterize protein complexes ICP4 participates 
in during infection.  The use of TAP allowed for the gentle, yet specific isolation of ICP4 and 
associated proteins.  It is possible, however, that these complexes were not representative of 
those formed in vivo, but of those form in vitro during the purification steps.  The high salt-
dependent copurification but not nuclear extraction of TBP and TAF1 with ICP4 (figure 15) 
suggests these complexes are indeed formed in the nucleus and not during later purification 
steps.  The copurification of several members of large cellular complexes show that the TAP 
method was able to isolate large, ICP4 containing complexes; however, it makes it difficult to 
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draw any conclusions about direct protein:protein interactions made by ICP4.  It does, however 
provide general insight into what protein complexes are involved in ICP4-mediated transcription.  
Viral gene expression follows a highly regulated cascade of IE, E, and L genes.  
Specifically how this cascade is attained is not completely understood, but several lines of 
evidence show that E and L genes are differentially activated both from the cellular and the viral 
standpoint.  Efficient activation of E genes is dependent on the action of upstream cellular 
activators, such as Sp1, and the GTF TFIIA, whereas L gene activation is not (35, 178).  Proper 
L gene expression requires DNA replication, the Inr element, and the C-terminal transactivation 
domain of ICP4, whereas E gene expression does not (93, 140).  Indeed, loss of the C-terminus 
of ICP4, and thus the ICP4-TAF1 interaction, disrupts L but not E gene expression, as well as the 
recruitment of TBP to L but not E promoters (247).  This suggests ICP4-mediated recruitment of 
TBP to the different gene classes is through distinct mechanisms and that this difference may 
specifically be the context in which TBP is recruited.  The observation that ICP4 forms two 
distinct complexes with TBP, one with and without TAF1 (figure 15), further supports this 
hypothesis. 
That TFIIA expression is impaired at late times of infection has been well established 
(312). Additionally, TFIIA is dispensable for L but not E gene expression in an Inr element 
dependent manner (312).  Interestingly, TFII-I-induced PICs are distinct from those formed by 
TFIIA, further supporting the role of TFII-I specifically in L gene expression (237).  TFIIA has a 
wide role in transcription which includes stabilization of free TBP monomer interacting at the 
promoter (36).  TFIIA also plays a role in recruiting TBP to promoters mediated by the yeast 
SAGA complex (291), a homolog of the TAF containing complex STAGA.  This and the 
copurification of the TAF stable-subcomplex thought to act as a scaffold for the formation of 
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both TFIID and the other TAF-containing complexes suggest that ICP4-mediated recruitment of 
TBP to E genes may not be through TFIID but through the other TAF-containing complexes. 
The studies described here provide great insight into the mechanism of ICP4 
transactivation of viral genes.  They show that ICP4 has a broad role in transcription, acting at 
the promoter through interactions with the GTFs through TBP and TAFs as well as TFII-I and 
through interactions with upstream cofactors such as the mediator complex.  The investigation 
into the specific role of some of these interactions on activation at specific promoter classes will 
further understanding both of the global regulation of viral genes as well as cellular transcription 
in general.  HSV provides a unique system in which to study the role of upstream activators, core 
promoter elements such as Inr sequences, and formation of distinct PICs in transcription.  It is 
clear ICP4 activates transcription through interactions with a variety of cellular factors.  It is 
likely the mechanism of ICP4 transactivation of E and L genes is through recruitment of distinct 
cellular complexes.  Direct analysis of occupancy related to ICP4 at E and L promoters is 
necessary to fully understand the local function of ICP4 and the global regulation of the viral 
gene cascade. 
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5.0  SUMMARY AND GENERAL DISCUSSION 
HSV gene expression follows a strictly regulated temporal cascade that can be divided into three 
broad phases: the IE, E, and L genes.  This cascade is regulated by a complex physical and 
functional interaction between viral and cellular factors.  ICP4, the major viral transcription 
regulator, is required for the proper expression of all three classes.  Through its repression of its 
own IE expression and transactivation of E and L genes, ICP4 plays a crucial role in the viral 
lifecycle (48, 67, 84, 86, 197, 198, 224).  In addition, HSV infection dramatically alters the 
makeup of the cellular transcription machinery during the course of infection (77, 139, 229, 312).  
Thus, ICP4 must be able to regulate transcription from a diverse set of promoters in a changing 
cellular transcription mileu.  ICP4 has previously been shown to have N- and C-terminal 
transcriptional regulatory domains that interact with TBP and TAF1 of TFIID to both activate 
and repress transcription (26, 92, 145, 256, 266).  While the N- and C-terminal regulatory 
domains are separated by a large stretch of amino acids in the primary sequence, temperature-
sensitive mutations in the C-terminus can impact the function of the N-terminus (37).  ICP4’s 
large size, complex structure, and ability to act at diverse promoters and in changing 
environments, led to the hypothesis that ICP4’s transcriptional regulatory domains come together 
to form a tertiary structure, providing large surfaces for interactions with a variety of cellular and 
possibly viral proteins to orchestrate the gene expression cascade.  The goals of the study were to 
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characterize the N-terminal regulatory domain and the role of the C-terminus in its function and 
to investigate the various protein interactions made by ICP4, in vivo. 
To characterize the N-terminal regulatory domain, deletion mutants dissecting the region 
were made.  These deletions were made both with and without an intact C-terminal domain in 
order to to determine the role of the C-terminus in the function of the N-terminal domain.  In this 
study, we show that the entire N-terminal regulatory domain is necessary for viral replication and 
ICP4 function, since viruses expressing ICP4 with either the 3-8 (aa 30-142) or 8-10 (aa 142-
210) deletions exhibited reduced viral replication (figure 7), altered protein expression profiles 
(figure 8), and reduced transactivation of E and L genes (figure 9).  Loss of either the 3-8 or 8-10 
region did not affect ICP4’s ability to repress its own transcription (figure 9) or to bind DNA 
(figure 10).  The mutants lacking the 3-8 region showed a slightly greater reduction in viral 
growth compared to the 8-10 deletion (figure 7) but a more dramatic reduction in the 
transactivation function, as exhibited by both protein expression (figure 8) and abundance of tk 
and gC mRNA (figure 9).  These data suggest that while both the 3-8 and 8-10 region play an 
important role in ICP4 function, the 3-8 region may be more directly responsible for ICP4 
transactivation.   
ICP4 exhibits several regions of similarity with other alpha-herpesviruses that correspond 
to functional domains (30, 174).  Interestingly, the N-terminal regulatory domain shares the least 
similarity with IE62.  The polyserine tract found in the N-terminus is the only region with 
significant similarity to IE62 and is contained in the 8-10 region.  The 3-8 deletion, which is 
shown to be important for ICP4 function by this study, does not contain any significant similarity 
to IE62.  Sequence alignments of the ICP4 sequences from HSV-1, HSV-2, and herpes B virus, 
however, revealed some discreet regions of similarity, including one between aa 81-90 within the 
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3-8 deletion (figure 13).  The observation that both regions shown to be important for ICP4 
function include regions of similary conserved amongst closely related viruses suggest that these 
conserved regions may be responsible for the function attributed to 3-8 and 8-10 deletions. The 
fact that these regions are conserved amongst differing groups of viruses suggests they play 
distinct roles in ICP4’s function, an observation borne out by this study.   Further studies using 
targeted deletions of these conserved regions will provide further insight into ICP4’s function.   
The second goal of this study was to isolate and characterize the proteins with which 
ICP4 interacts during infection.  Tandem affinity purification was used to isolate ICP4 
complexes from infected cells.  These complexes were subsequently characterized through a 
combination of mass spectroscopic and western blot analyses.  Using MS, we were able to 
identify, with high confidence, a number of proteins that interact with ICP4 (table 2).  The 
identification of proteins previously shown to interact with ICP4, such as TBP, TAF1, and L22, 
verify the efficacy both of the TAP isolation and the methods used to identify potential 
interactors (figure 18, table 2).  Of particular interest were TBP and the TAFs, Med8, and TFII-I.  
The mass spec analysis identified TBP and TAFs 3, 4, 4B, 5, 6, 9B, 10, and 13.  Western blot 
analysis verifies the TBP and TAF4 analysis and also identified TAFs 1 and 7 (figure 18).  ICP4 
has previously been shown to stabilize TFIID binding to promoters in vitro (26, 92).  The 
association with TBP and the TAFs in this study, both in the MS and western blot data, 
reinforces these findings.  There are other TAF containing complexes that exist in the cell in 
addition to TFIID, however, and these complexes include several of the TAFs that co-purify with 
ICP4, specifically, TAF4, TAF5, TAF6, TAF9b, and TAF10.  These complexes, including 
TFTC, STAGA, and PCAF, all play a role in activator-dependent transcription, adopt structures 
similar to that of TFIID, and share many of the same enzymatic activities, including HAT, as 
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TFIID (reviewed in (192)).  Recently, a core TAF-subcomplex consisting of TAF4, TAF5, 
TAF6, TAF9, and TAF12 has been proposed.  This subcomplex acts as a scaffold on which all of 
the TAF-containing complexes are formed (300).  The entire TAF subcomplex was identified by 
MS or western blot in the ICP4 complexes, suggesting ICP4 may associate with this core 
subcomplex.  The copurification of the TFIID-specific TAF1, TAF3, TAF4b, TAF7, and TAF13 
confirms the presence of TFIID and shows ICP4 activates transcription from at least some viral 
promoters through the stabilization of TFIID on these promoters.  ICP4’s association with the 
proposed TAF-subcomplex raises the possibility of an interaction with one or more of the other 
TAF-containing complexes, in addition to TFIID. 
The Mediator complex was also shown to associate with ICP4.  The mediator acts as a 
general cofactor, bridging activators and the general transcription machinery, primarily through 
facilitating the entry of pol II into the PIC (129, 154, 276, 279).  It also plays a role in activator-
dependent stabilization of the scaffold complex that enhances transcription reinitiation from the 
same promoter (311).  Several different forms of mediator have been isolated, dependent on the 
technique used for isolation, suggesting the mediator complex consists of a core complex that 
associates with other proteins depending on the transcriptional environment (reviewed in (278)).  
The complex can be divided into three domains, the head, middle and tail.  The head domain 
primarily interacts with pol II while the middle and tail domains interact with upstream 
activators, thus executing its bridging function (18, 27, 38). The presence of Mediator in the TAP 
sample was shown both by MS (Med8) and western blot (Med7, TRAP220, and CRSP77).  In 
addition, immunofluorescence studies of infected cells showed a significant reorganization of 
TRAP220 during infection, with strong co-localization of ICP4 and TRAP220 starting at early 
and proceeding through late times of infection (figure 19).  Thus, we were able to show an ICP4-
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mediator interaction through western blot (figure 19), mass spectrometry (table 2), and through 
the strong co-localization of ICP4 and TRAP220 during infection (figure 19).  The mediator 
subunits identified in this study are found in different regions of the mediator complex; both 
Med8 and CRSP77 localize to the head region of mediator while Med7 and TRAP220 are found 
in the middle.  The copurification of components of two distinct regions of mediator suggests the 
involvement of the entire mediator complex in viral transcription.   These data confirm a role for 
Mediator in viral growth starting early in infection and continuing into late in infection.  In 
addition, ChIP analysis shows that Mediator is indeed recruited to viral promoters in an ICP4-
dependent manner, showing a role for Mediator specifically in ICP4-mediated activation. The 
characterization of Med7, Med8, TRAP220, and CRSP77 is the first evidence showing a role for 
mediator in ICP4-mediated activation and suggests ICP4 plays a larger role than solely direct 
TFIID stabilization onto the promoter. 
The final protein of interest is the general transcription factor TFII-I.  TFII-I is involved 
in both basal and activated transcription through its recognition of the Inr element of the core 
promoter (238).  It is required, along with TFIID, for activation of TATA- Inr+ but not TATA+ 
promoters (168).   In addition, TFII-I initiates the formation of PICs that are distinct from those 
formed by TFIIA, as shown by differential mobility in EMSA studies (237).  This suggests that 
ICP4-mediated activation of L genes through recruitment of TFIID may also involve TFII-I. 
Although TFII-I was identified with high confidence in the TAP sample by MS, its presence 
could not be confirmed by western blot or immunofluorescence.  This does not necessarily refute 
a potential ICP4-TFII-I interaction, as ICP4 may interact with a form of TFII-I that is not 
recognized by the monoclonal antibody used in these assays.  Further study needs to be 
performed to clarify the role TFII-I plays in ICP4 mediated transactivation of genes.   
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It is clear from these studies that ICP4 does indeed interact with a variety of cellular 
factors to regulate transcription.  These interactions are facilitated through the functional 
domains outline above.  The N-terminal regulatory domain interacts with TBP while the C-
terminus interacts with TAF1 (26, 266).  Is unclear what regions mediate ICP4’s interaction with 
Mediator or TFII-I, however.  ICP4 and IE62 share significant regions of homology, especially 
in the C-terminus, and both interact with Mediator.  IE62 interacts with Mediator through an 
acidic activation domain found in its N-terminus (307).  ICP4, however, does not encode an 
acidic activation domain making it unclear which region or regions of ICP4 are necessary for 
interaction with Mediator.  The regions of ICP4 that interact with TFII-I are also not clear.  As 
described earlier however, its probable role in L gene expression implicates the C-terminus.  
Studies combining the deletion mutants described above and TAP purification and 
characterization of ICP4-containing protein complexes would provide insight into which region 
or regions of ICP4 are necessary for interactions with the cellular machinery.   This in turn will 
lead to a better understanding of ICP4 function and the regulation of viral gene expression.  
The data obtained through TAP provide general insight into ICP4-mediated transcription 
and the regulation of the viral cascade of transcription.  Viral gene expression follows a highly 
regulated cascade of IE, E, and L genes.  Specifically how this cascade is attained is not 
completely understood, but several lines of evidence show that E and L genes are differentially 
activated both from the cellular and the viral standpoint.  E gene promoters contain binding sites 
for several cellular upstream activators, such as Sp1, which serve to recruit and stabilize the PIC 
at the promoter (132).  L genes, in contrast, are very simple and consist only of a TATA box and 
an Inr element (97, 98, 273).  The Inr element is a common cellular promoter element recognized 
by TAF1 of TFIID that is required specifically for L gene expression (28, 93, 140).  In addition 
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to TFIID, TFII-I recognizes the Inr element and both TFII-I and TFIID have been shown to be 
necessary for activation of Inr driven promoters (168, 238).  This strongly implicates both TFII-I 
and TFIID specifically in L gene expression.  Loss of the C-terminus of ICP4, and thus the ICP4-
TAF1 interaction, disrupts L but not E gene expression, as well as the recruitment of TBP to L 
but not E promoters (247).  This suggests ICP4-mediated recruitment of TBP to the different 
gene classes is through distinct mechanisms and that this difference may specifically be the 
context in which TBP is recruited. 
The final difference in PIC formation at E and L promoters is the involvement of the 
GTF, TFIIA.  Previous studies have shown that TFIIA expression is impaired at late times of 
infection.  In addition, TFIIA is dispensable for L but not E gene expression in an Inr element 
dependent manner (312).  TFIIA has a broad role in transcription, including stabilization of free 
TBP monomer binding to the promoter (36).  In addition, TFIIA has been implicated in the 
recruitment of TBP to promoters mediated by the yeast SAGA complex (291), a homolog of the 
TAF containing complex STAGA.  It is possible, in light of several lines of evidence outlined 
above, that ICP4-mediated recruitment of TBP to E genes may not be through TFIID but through 
the other TAF-containing complexes.  There is no direct evidence either for or against this, 
however it is an intriguing hypothesis that fits the known data. 
The further investigation into the specific role these proteins interactions have on ICP4-
mediated activation at specific promoter classes speculated on here will provide great insight 
both into the global regulation of viral genes as well as cellular transcription in general.  HSV 
provides a unique system in which to study the role of upstream activators, core promoter 
elements such as Inr sequences, and the involvement of TFIIA in transcription. Unfortunately, 
the traditional methods of separating E and L gene expression via use of viral DNA replication 
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inhibitors and time post-infection are confounded by the finding that ICP4, TBP, and pol II can 
all be found on L promoters early in infection in the presence of PAA (247).  Thus, direct 
analysis of viral promoter occupancy via ChIP may be necessary to answer several of the 
questions raised here. 
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